PRODUCT MONOGRAPH

INCLUDING PATIENT MEDICATION INFORMATION



powder for solution for infusion 50 mg solution for infusion 100 mg/4mL vial

Antineoplastic agent, monoclonal antibody

KEYTRUDA[®] has been issued marketing authorization **with conditions**, pending the results of studies to verify its clinical benefit. Patients should be advised of the nature of the authorization. For further information for KEYTRUDA[®], please refer to Health Canada's Notice of Compliance with conditions – drug products website: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/notices-avis/conditions/index-eng.php

KEYTRUDA® is indicated for the treatment of patients with:

- Metastatic non-small cell lung carcinoma (NSCLC) as monotherapy, in adults whose tumours express PD-L1 [(Tumour Proportion Score (TPS) ≥ 1%)] as determined by a validated test and who have disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumour aberrations should have received authorized therapy for these aberrations prior to receiving KEYTRUDA[®].
- refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, in adults who have failed autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) or who are not ASCT candidates and have failed BV.

KEYTRUDA[®] has been issued marketing authorization **without conditions** for the treatment of patients with:

- Unresectable or metastatic melanoma who have not received prior treatment with ipilimumab. Subjects with BRAF V600 mutant melanoma may have received prior BRAF inhibitor therapy.
- Unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor.
- Metastatic non-small cell lung carcinoma (NSCLC) as monotherapy, in adults whose tumours have high PD-L1 expression (TPS ≥50%) as determined by a validated test, with no EGFR or ALK genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC.
- Locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of completing neoadjuvant or adjuvant platinum-containing chemotherapy.

Merck Canada Inc. 16750 route Transcanadienne Kirkland QC Canada H9H 4M7

http://www.merck.ca

Submission Control No: 213539

Date of Approval: March 23, 2018

This product has been approved under the Notice of Compliance with Conditions (NOC/c) policy for one or all of its indicated uses.

What is a Notice of Compliance with Conditions (NOC/c)?

An NOC/c is a form of market approval granted to a product on the basis of **promising** evidence of clinical effectiveness following review of the submission by Health Canada.

Products approved under Health Canada's NOC/c policy are intended for the treatment, prevention or diagnosis of a serious, life-threatening or severely debilitating illness. They have demonstrated promising benefit, are of high quality and possess an acceptable safety profile based on a benefit/risk assessment. In addition, they either respond to a serious unmet medical need in Canada or have demonstrated a significant improvement in the benefit/risk profile over existing therapies. Health Canada has provided access to this product on the condition that sponsors carry out additional clinical trials to verify the anticipated benefit within an agreed upon time frame.

What will be different about this Product Monograph?

The following Product Monograph will contain boxed text at the beginning of each major section clearly stating the nature of the market authorization. Sections for which NOC/c status holds particular significance will be identified in the left margin by the symbol NOC/c. These sections may include, but are not limited to, the following:

- Indications and Clinical Uses:
- Action;
- Warnings and Precautions;
- Adverse Reactions;
- Dosage and Administration; and
- Clinical Trials.

Adverse Reaction Reporting and Re-Issuance of the Product Monograph

Health care providers are encouraged to report Adverse Drug Reactions associated with normal use of these and all drug products to Health Canada's Canada Vigilance Program at 1-866-234-2345. The Product Monograph will be re-issued in the event of serious safety concerns previously unidentified or at such time as the sponsor provides the additional data in support of the product's clinical benefit. Once the latter has occurred, and in accordance with the NOC/c policy, the conditions associated with market authorization will be removed.

Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION	5
SUMMARY PRODUCT INFORMATION	
DESCRIPTION	
INDICATIONS AND CLINICAL USE	6
CONTRAINDICATIONS	7
WARNINGS AND PRECAUTIONS	7
ADVERSE REACTIONS	12
DRUG INTERACTIONS	35
DOSAGE AND ADMINISTRATION	
OVERDOSAGE	39
ACTION AND CLINICAL PHARMACOLOGY	
STORAGE AND STABILITY	42
SPECIAL HANDLING INSTRUCTIONS	42
DOSAGE FORMS, COMPOSITION AND PACKAGING	42
PART II: SCIENTIFIC INFORMATION	43
PHARMACEUTICAL INFORMATION	44
TOXICOLOGY	69
REFERENCES	75
PART III: PATIENT MEDICATION INFORMATION	76



PART I: HEALTH PROFESSIONAL INFORMATION

KEYTRUDA[®] has been issued marketing authorization **with conditions**, pending the results of studies to verify its clinical benefit. Patients should be advised of the nature of the authorization. For further information for KEYTRUDA[®], please refer to Health Canada's Notice of Compliance with conditions – drug products website: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/notices-avis/conditions/index-eng.php

KEYTRUDA® is indicated for the treatment of patients with:

- Metastatic non-small cell lung carcinoma (NSCLC) as monotherapy, in adults whose tumours express PD-L1 [(Tumour Proportion Score (TPS) ≥ 1%)] as determined by a validated test and who have disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumour aberrations should have received authorized therapy for these aberrations prior to receiving KEYTRUDA[®].
- refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, in adults who have failed autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) or who are not ASCT candidates and have failed BV.

KEYTRUDA[®] has been issued marketing authorization **without conditions** for the treatment of patients with:

- Unresectable or metastatic melanoma who have not received prior treatment with ipilimumab. Subjects with BRAF V600 mutant melanoma may have received prior BRAF inhibitor therapy.
- Unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor.
- Metastatic non-small cell lung carcinoma (NSCLC) as monotherapy, in adults whose tumours have high PD-L1 expression (TPS ≥50%) as determined by a validated test, with no EGFR or ALK genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC.
- Locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of completing neoadjuvant or adjuvant platinum-containing chemotherapy.

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	Clinically Relevant Nonmedicinal Ingredients
Intravenous infusion	Powder for solution for infusion 50 mg Solution for infusion 100 mg/4mL vial	None For a complete listing see Dosage Forms, Composition and Packaging section.

DESCRIPTION

KEYTRUDA® (pembrolizumab) is a selective humanized monoclonal antibody designed to block the interaction between programmed cell death receptor-1 (PD-1) and its ligands, PD-L1 and PD-L2. Pembrolizumab is an IgG4 kappa immunoglobulin with an approximate molecular weight of 149 kDa.

INDICATIONS AND CLINICAL USE

Melanoma

KEYTRUDA[®] is indicated for the treatment of patients with unresectable or metastatic melanoma who have not received prior treatment with ipilimumab. Subjects with BRAF V600 mutant melanoma may have received prior BRAF inhibitor therapy.

KEYTRUDA[®] is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor.

Non-Small Cell Lung Carcinoma

KEYTRUDA® as monotherapy is indicated for the treatment of metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours have high PD-L1 expression [Tumour Proportion Score (TPS) \geq 50%] as determined by a validated test, with no EGFR or ALK genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC.

NOC/c KEYTRUDA® as monotherapy is indicated for the treatment of metastatic non-small cell lung carcinoma (NSCLC), in adults whose tumours express PD-L1 (TPS \geq 1%) as determined by a validated test and who have disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumour aberrations should have received an authorized therapy for these aberrations prior to receiving KEYTRUDA®.

NOC/c Hodgkin Lymphoma

KEYTRUDA® as monotherapy is indicated for the treatment of adult patients with refractory or relapsed classical Hodgkin Lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) or who are not ASCT candidates and have failed BV. An improvement in survival or disease-related symptoms has not yet been established.

Urothelial Carcinoma

KEYTRUDA[®] is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of completing neoadjuvant or adjuvant platinum-containing chemotherapy.

Geriatrics (> 65 years of age):

No overall differences in safety or efficacy were reported between elderly patients (65 years and over) and younger patients (less than 65 years). Limited safety and efficacy information is available for KEYTRUDA® in cHL \geq 65 years of age (n=20) (See WARNINGS AND PRECAUTIONS; Geriatrics).

Pediatrics (<18 years of age):

Safety and efficacy of KEYTRUDA® in pediatric patients have not been established.

NOC/c CONTRAINDICATIONS

KEYTRUDA[®] is contraindicated in patients who have experienced a severe hypersensitivity reaction (See WARNINGS AND PRECAUTIONS) to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING section of the Product Monograph.

NOC/c WARNINGS AND PRECAUTIONS

General

KEYTRUDA® (pembrolizumab) should be administered under the supervision of physicians experienced in the treatment of cancer.

The data described in the WARNINGS AND PRECAUTIONS section reflect exposure to KEYTRUDA® as monotherapy in 2799 patients in three randomized, open-label, active-controlled clinical trials (KEYNOTE-002, KEYNOTE-006, and KEYNOTE-010), which enrolled 912 patients with melanoma and 682 patients with NSCLC, and one single-arm trial (KEYNOTE-001) which enrolled 655 patients with melanoma and 550 patients with NSCLC (See CLINICAL TRIALS). This is termed the Reference Safety Data set and will be referred to as the data set against which safety data from the first-line NSCLC and second-line urothelial cancer indications were compared.

Immune-mediated adverse reactions:

Immune-mediated adverse reactions occurred in patients receiving KEYTRUDA[®]. In clinical trials, most immune-mediated adverse reactions were reversible and managed with interruptions of KEYTRUDA[®], administration of corticosteroids and/or supportive care. Immune-mediated adverse reactions have also occurred after the last dose of KEYTRUDA[®]. Immune-mediated adverse reactions affecting more than one body system can occur simultaneously.

For suspected immune-mediated adverse reactions, ensure adequate evaluation to confirm etiology or exclude other causes. Based on the severity of the adverse reaction, withhold KEYTRUDA® and consider administration of corticosteroids. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Based on limited data from clinical studies in patients whose immune-mediated adverse reactions could not be controlled with corticosteroid use, administration of other systemic immunosuppressants can be considered. KEYTRUDA® may be restarted within 12 weeks after last dose of KEYTRUDA® if the adverse reaction remains at Grade ≤ 1 and corticosteroid dose has been reduced to ≤ 10 mg prednisone or equivalent per day. KEYTRUDA® must be permanently discontinued for any Grade 3 immune-mediated adverse reaction that recurs and for any Grade 4 immune-mediated adverse reaction toxicity, except for endocrinopathies that are controlled with replacement hormones (See DOSAGE AND ADMINISTRATION, and ADVERSE REACTIONS).

Immune-mediated pneumonitis:

KEYTRUDA[®] can cause immune-mediated pneumonitis, including fatal cases. Monitor patients for signs and symptoms of pneumonitis. Evaluate patients with suspected pneumonitis with radiographic imaging and administer corticosteroids (initial dose of 1 to 2 mg/kg/day prednisone or equivalent followed by a taper) for Grade 2 or greater pneumonitis. Withhold KEYTRUDA[®] for moderate (Grade 2) pneumonitis, and permanently discontinue KEYTRUDA[®] for severe (Grade 3) life-threatening (Grade 4) or recurrent moderate (Grade 2) pneumonitis (See DOSAGE AND ADMINISTRATION and ADVERSE REACTIONS).

Pneumonitis occurred in 94 (3.4%) of the 2799 patients in the Reference Safety Data set, including Grade 2 (1.3%), 3 (0.9%), 4 (0.3%), or 5 (0.1%) pneumonitis.

Immune-mediated colitis:

KEYTRUDA[®] can cause immune-mediated colitis. Monitor patients for signs and symptoms of colitis. Administer corticosteroids (initial dose of 1 to 2 mg/kg/day prednisone or equivalent followed by a taper) for Grade 2 or greater colitis. Withhold KEYTRUDA[®] for moderate (Grade 2) or severe (Grade 3) colitis, and permanently discontinue KEYTRUDA[®] for life-threatening (Grade 4) colitis (See DOSAGE AND ADMINISTRATION and ADVERSE REACTIONS).

Colitis occurred in 48 (1.7%) of the 2799 patients in the Reference Safety Data set, including Grade 2 (0.4%), Grade 3 (1.1%), and Grade 4 (<0.1%) colitis.

Immune-mediated hepatitis:

KEYTRUDA® can cause immune-mediated hepatitis. Monitor patients for changes in liver function. Administer corticosteroids (initial dose of 0.5 to 1 mg/kg/day [for Grade 2 hepatitis]

and 1 to 2 mg/kg/day [for Grade 3 or greater hepatitis] prednisone or equivalent followed by a taper) and, based on severity of liver enzyme elevations, withhold or discontinue KEYTRUDA® (See DOSAGE AND ADMINISTRATION and ADVERSE REACTIONS).

Hepatitis occurred in 19 (0.7%) of the 2799 patients in the Reference safety Data set, including Grade 2 (0.1%), Grade 3 (0.4%), and Grade 4 (<0.1%) hepatitis.

Immune-mediated nephritis and renal dysfunction:

KEYTRUDA[®] can cause immune-mediated nephritis. Monitor patients for changes in renal function. Administer corticosteroids (initial dose of 1 to 2 mg/kg/day prednisone or equivalent followed by a taper) for Grade 2 or greater nephritis. Withhold KEYTRUDA[®] for moderate (Grade 2), and permanently discontinue KEYTRUDA[®] for severe (Grade 3) or life-threatening (Grade 4) nephritis (See DOSAGE AND ADMINISTRATION and ADVERSE REACTIONS).

Nephritis occurred in 9 (0.3%) of the 2799 patients in the Reference Safety Data set, including Grade 2 (0.1%), Grade 3 (0.1%), and Grade 4 (<0.1%) nephritis.

<u>Immune mediated endocrinopathies:</u>

Severe endocrinopathies, including hypophysitis, type 1 diabetes mellitus, diabetic ketoacidosis, hypothyroidism, and hyperthyroidism have been observed with KEYTRUDA® treatment.

Long-term hormone replacement therapy may be necessary in cases of immune-related endocrinopathies.

Hypophysitis

KEYTRUDA® can cause hypophysitis. Monitor patients for signs and symptoms of hypophysitis (including hypopituitarism and adrenal insufficiency). Administer corticosteroids and hormone replacement as clinically indicated. Withhold KEYTRUDA® for moderate (Grade 2) hypophysitis and withhold or discontinue KEYTRUDA® for severe (Grade 3) or life-threatening (Grade 4) hypophysitis (See DOSAGE AND ADMINISTRATION and ADVERSE REACTIONS).

Hypophysitis occurred in 17 (0.6%) of the 2799 patients in the Reference Safety Data set, including Grade 2 (0.2%), Grade 3 (0.3%), and Grade 4 (<0.1%) hypophysitis.

Type 1 diabetes mellitus

KEYTRUDA® can cause type 1 diabetes mellitus, including diabetic ketoacidosis, which have been reported in 6 (0.2%) of 2799 patients receiving KEYTRUDA®. Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Administer insulin for type 1 diabetes, and withhold KEYTRUDA® in cases of severe hyperglycemia until metabolic control is achieved.

Thyroid disorders

KEYTRUDA® can cause thyroid disorders, including hyperthyroidism, hypothyroidism, and thyroiditis, which can occur at any time during treatment; therefore, monitor patients for changes in thyroid function (at the start of treatment, periodically during treatment and as indicated based

on clinical evaluation) and clinical signs and symptoms of thyroid disorders. Hypothyroidism may be managed with replacement therapy without treatment interruption and without corticosteroids. Hyperthyroidism may be managed symptomatically. Withold or discontinue KEYTRUDA® for severe (Grade 3) or life-threatening (Grade 4) hyperthyroidism (See DOSAGE AND ADMINISTRATION and Immune-mediated adverse reactions above).

Hyperthyroidism occurred in 96 (3.4%) of the 2799 patients in the Reference Safety Data set, including Grade 2 (0.8%) and Grade 3 (0.1%) hyperthyroidism.

Hypothyroidism occurred in 237 (8.5%) of 2799 patients in the Reference Safety Data set, including Grade 3 (0.1%) hypothyroidism.

Severe skin reactions

KEYTRUDA[®] can cause immune-mediated severe skin reactions. Monitor patients for suspected severe skin reactions and exclude other causes. Based on the severity of the adverse reaction, withhold or permanently discontinue KEYTRUDA[®] and administer corticosteroids (see Dosage and Administration).

Cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), some with fatal outcome, have been reported in patients treated with KEYTRUDA[®]. For signs or symptoms of SJS or TEN, withhold KEYTRUDA[®] and refer the patient for specialized care for assessment and treatment. If SJS or TEN is confirmed, permanently discontinue KEYTRUDA[®] (See Dosage and Administration).

Other immune-mediated adverse reactions:

KEYTRUDA[®] can cause other clinically important immune-mediated adverse reactions including severe and fatal cases.

Based on the severity of the adverse reaction, KEYTRUDA® should be withheld and corticosteroids administered.

The following additional clinically significant, immune-mediated adverse reactions were reported in less than 1% (unless otherwise indicated) of the 2799 patients treated with KEYTRUDA® in the Reference Safety Data set: uveitis, arthritis (1.5%), myositis, encephalitis, sarcoidosis, myasthenic syndrome, vasculitis, Guillain-Barré syndrome, hemolytic anemia, and pancreatitis.

The following was reported in other clinical studies with KEYTRUDA® or in post-marketing use: myocarditis.

Solid organ transplant rejection has been reported in the post-marketing setting in patients treated with KEYTRUDA[®]. Treatment with KEYTRUDA[®] may increase the risk of rejection in solid organ transplant recipients. Consider the benefit of treatment with KEYTRUDA[®] versus the risk of possible organ rejection in these patients.

Increased mortality in patients with multiple myeloma when KEYTRUDA® is added to a

thalidomide analogue and dexamethasone:

In two randomized clinical trials in patients with multiple myeloma, the addition of KEYTRUDA® to a thalidomide analogue plus dexamethasone, a use for which no PD-1 or PD-L1 blocking antibody is indicated, resulted in increased mortality. Treatment of patients with multiple myeloma with a PD-1 or PD-L1 blocking antibody in combination with a thalidomide analogue plus dexamethasone is not recommended outside of controlled clinical trials.

<u>Complications of allogeneic Hematopoietic Stem Cell Transplant (HSCT)</u> Allogeneic HSCT after treatment with KEYTRUDA[®]:

Cases of graft-versus-host-disease (GVHD) and hepatic veno-occlusive disease (VOD) have been observed in patients with classical Hodgkin lymphoma undergoing allogeneic HSCT after previous exposure to KEYTRUDA[®]. Until further data become available, careful consideration to the potential benefits of HSCT and the possible increased risk of transplant-related complications should be made case by case (See ADVERSE REACTIONS).

Allogeneic HSCT prior to treatment with KEYTRUDA®:

In patients with a history of allogeneic HSCT, acute GVHD, including fatal GVHD, has been reported after treatment with KEYTRUDA[®]. Patients who experienced GVHD after their transplant procedure may be at an increased risk for GVHD after treatment with KEYTRUDA[®]. Consider the benefit of treatment with KEYTRUDA[®] versus the risk of possible GVHD in patients with a history of allogeneic HSCT.

Infusion-related reactions:

KEYTRUDA[®] can cause severe infusion-related reactions, including hypersensitivity and anaphylaxis, which have been reported in 6 (0.2%) of the 2799 patients receiving KEYTRUDA[®] in the Reference Safety Data set. For severe or life-threatening infusion reactions, stop infusion and permanently discontinue KEYTRUDA[®] (See DOSAGE AND ADMINISTRATION). Patients with mild or moderate infusion reaction may continue to receive KEYTRUDA[®] with close monitoring; premedication with antipyretic and antihistamine may be considered.

Embryofetal toxicity:

KEYTRUDA[®] can cause fetal harm. Pregnant women or women with childbearing potential should be advised of the potential risk to the fetus (See Special Populations, Pregnant Women).

Special Populations

Pregnant Women: There are no data on the use of pembrolizumab in pregnant women. Animal reproduction studies have not been conducted with pembrolizumab; however, blockade of PD-L1 signaling has been shown in murine models of pregnancy to disrupt tolerance to the fetus and to result in an increase in fetal loss (See TOXICOLOGY). These results indicate a potential risk, based on its mechanism of action, that administration of KEYTRUDA[®] during pregnancy could cause fetal harm, including increased rates of abortion or stillbirth. Human IgG4 (immunoglobulin) is known to cross the placental barrier and pembrolizumab is an IgG4; therefore, pembrolizumab has the potential to be transmitted from the mother to the developing

fetus. KEYTRUDA® is not recommended during pregnancy unless the clinical benefit outweighs the potential risk to the fetus. Women of childbearing potential should use effective contraception during treatment with KEYTRUDA® and for 4 months after the last dose of KEYTRUDA®.

Nursing Women: It is unknown whether KEYTRUDA[®] is secreted in human milk. Because many drugs are secreted in human milk, a decision should be made whether to discontinue breast-feeding or to discontinue KEYTRUDA[®], taking into account the benefit of breast feeding for the child and the benefit of KEYTRUDA[®] therapy for the woman.

Pediatrics (< 18 years of age): Safety and efficacy of KEYTRUDA® in pediatric patients of age have not been established.

Geriatrics (> **65 years of age**): No overall differences in safety or efficacy were reported between elderly patients (65 years and over) and younger patients (less than 65 years). No dose adjustment is necessary in this population. Limited safety and efficacy information is available for KEYTRUDA[®] in cHL patients \geq 65 years of age (n=20).

Hepatic Impairment: No dose adjustment is needed for patients with mild hepatic impairment. KEYTRUDA[®] has not been studied in patients with moderate or severe hepatic impairment (See DOSAGE AND ADMINISTRATION).

Renal Impairment: No dose adjustment is needed for patients with mild (estimated Glomerular Filtration Rate (eGFR) <90 and \geq 60 mL/min/1.73 m²) or moderate (eGFR <60 and \geq 30 mL/min/1.73 m²) renal impairment. KEYTRUDA[®] has not been studied in patients with severe (eGFR <30 and \geq 15 mL/min/1.73 m²) renal impairment (See DOSAGE AND ADMINISTRATION).

Monitoring and Laboratory Tests:

Liver function tests (hepatic transaminase and bilirubin levels), thyroid function tests and serum electrolytes should be monitored at the start of treatment, periodically during treatment and as indicated based on clinical evaluation. Patients should be closely monitored during treatment for signs and symptoms of immune-mediated adverse reactions, including but not limited to, dyspnea, hypoxia; increased frequency of bowel movements, diarrhea; elevated transaminase and bilirubin levels, elevated creatinine levels; rash, pruritus; headache, fatigue, hypotension, mental status changes, visual disturbances; muscle pain or weakness, paresthesias (See DOSAGE AND ADMINISTRATION and WARNINGS AND PRECAUTIONS).

NOC/c ADVERSE REACTIONS

Adverse Drug Reaction Overview

The safety and efficacy of KEYTRUDA® was investigated in 2799 patients treated with KEYTRUDA® in the Reference Safety Data set for the treatment of unresectable or metastatic melanoma or metastatic NSCLC. Overall, 1567 patients with melanoma (699 previously treated with ipilimumab and 868 naïve to ipilimumab) and 1232 patients with NSCLC were treated.

Safety is described for the pooled population of the 2799 patients that composed the Reference Safety Data set (studied across three doses; 2 mg/kg every 3 weeks and 10 mg/kg every 2 or 3 weeks). The median treatment duration was 4.2 months (range 1 day to 30.4 months) including 1153 patients treated for greater than or equal to six months and 600 patients treated for greater than or equal to one year.

KEYTRUDA® was discontinued for treatment-related adverse reactions in 5% of melanoma and NSCLC patients.

Treatment-related serious adverse events (SAEs) reported up to 90 days after the last dose occurred in 10% of patients receiving KEYTRUDA® (See WARNINGS AND PRECAUTIONS). Of these treatment-related SAEs, those occurring in more than ten patients (out of 2799) were: pneumonitis (n=44), colitis (n=25), diarrhea (n=17), and pyrexia (n=10).

Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

Immune-mediated adverse reactions

Immune-mediated adverse reactions are presented based on the 2799 patients treated with KEYTRUDA® in the Reference Safety Data set. The safety profile was generally similar for patients with melanoma and NSCLC.

Table 1 presents the incidence of immune-mediated adverse reactions by Grade that occurred in patients receiving KEYTRUDA[®].

Table 1: Immune-mediated Adverse Reactions

	2 1	KEYTRUDA [®] 2 mg/kg every 3 weeks or 10 mg/kg every 2 or 3 weeks n=2799										
Adverse	All Grades	All Grades Grade 2 Grade 3 Grade 4 Grade 5										
Reaction Hypothyroidism	(%) 8.5	(%) 6.2	(%) 0.1	(%) 0	(%) 0							
Hyperthyroidism	3.4	0.8	0.1	0	0							
Pneumonitis	3.4	1.3	0.9	0.3	0.1							
Colitis	1.7	0.4	1.1	< 0.1	0							
Hepatitis	0.7	0.1	0.4	< 0.1	0							
Hypophysitis	0.6	0.2	0.3	< 0.1	0							
Nephritis	0.3	0.1	0.1	< 0.1	0							
Type 1 Diabetes Mellitus	0.2	<0.1	0.1	0.1	0							

In patients with cHL (n=241) the incidence of hypothyroidism was 14.1% (all Grades) with 0.4% Grade 3.

Pneumonitis:

The median time to onset of pneumonitis was 3.3 months (range 2 days to 19.3 months), and the median duration was 1.5 months (range 1 day to 17.2+ months). Pneumonitis occurred more frequently in patients with a history of prior thoracic radiation (6.9%) than in patients who did not receive prior thoracic radiation (2.9%). Pneumonitis led to discontinuation of KEYTRUDA® in 36 (1.3%) patients. Pneumonitis resolved in 55/94 patients (59%).

Colitis:

The median time to onset of colitis was 3.5 months (range 10 days to 16.2 months), and the median duration was 1.3 months (range 1 day to 8.7+ months). Colitis led to discontinuation of KEYTRUDA[®] in 15 (0.5%) patients. Colitis resolved in 41/48 patients (85%).

Hepatitis:

The median time to onset of hepatitis was 1.3 months (range 8 days to 21.4 months), and the median duration was 1.8 months (range 8 days to 20.9+ months). Hepatitis led to discontinuation of KEYTRUDA® in 6 (0.2%) patients. Hepatitis resolved in 15/19 patients (79%).

Nephritis and renal dysfunction:

The median time to onset of nephritis was 5.1 months (range 12 days to 12.8 months), and the median duration was 3.3 months (range 12 days to 8.9+ months). Nephritis led to discontinuation of KEYTRUDA® in 3 (0.1%) patients. Nephritis resolved in 5/9 patients (56%).

Endocrinopathies:

Hypophysitis:

The median time to onset of hypophysitis was 3.7 months (range 1 day to 11.9 months), and the median duration was 4.7 months (range 8+ days to 12.7+ months). Hypophysitis led to discontinuation of KEYTRUDA® in 4 (0.1%) patients. Hypophysitis resolved in 7/17 patients (41%).

Hyperthyroidism:

The median time to onset of hyperthyroidism was 1.4 months (range 1 day to 21.9 months). The median duration was 2.1 months (range 3 days to 15.0+ months). Hyperthyroidism led to discontinuation of KEYTRUDA® in 2 (<0.1%) patients. Hyperthyroidism resolved in 71/96 patients (74%).

Hypothyroidism:

The median time to onset of hypothyroidism was 3.5 months (range 1 day to 18.9 months), and the median duration was not reached (range 2 days to 27.7+ months). One (<0.1%) patient discontinued KEYTRUDA[®] due to hypothyroidism.

Other adverse events

Melanoma

Treatment was discontinued for treatment-related adverse events in 5.4% of the 555 patients receiving KEYTRUDA[®] and in 9.4% of the 256 patients receiving ipilimumab.

In KEYNOTE-002, the adverse reaction profile was similar for the 2 mg/kg dose and 10 mg/kg dose, therefore summary safety results are provided in a pooled analysis (n=357) of both KEYTRUDA® arms. Adverse reactions resulting in permanent discontinuation occurred in 12% of patients receiving KEYTRUDA®; the most common (\geq 1%) were general physical health deterioration (1%), asthenia (1%), dyspnea (1%), pneumonitis (1%), and generalized edema (1%). Adverse reactions leading to interruption of KEYTRUDA® occurred in 14% of patients; the most common (\geq 1%) were dyspnea (1%), diarrhea (1%), and maculo-papular rash (1%). The most common adverse reactions (reported in at least 20% of patients) of KEYTRUDA® were fatigue, pruritus, rash, constipation, nausea, diarrhea, and decreased appetite.

There were no new safety signals observed at the final analysis and therefore with additional follow-up, no meaningful changes occurred in the safety profile of pembrolizumab.

Table 2 summarizes the treatment-related adverse events that occurred in at least 1% of patients with melanoma treated with KEYTRUDA[®] in KEYNOTE-006. The most common treatment-related adverse events (reported in at least 15% of patients) were diarrhea and fatigue.

In KEYNOTE-006, the adverse reaction profile was similar for the every 2 week and every 3 week schedule, therefore summary safety results are provided in a pooled analysis (n=555) of both KEYTRUDA® arms. Adverse reactions leading to permanent discontinuation of KEYTRUDA® occurred in 9% of patients. Adverse reactions leading to discontinuation of KEYTRUDA® in more than one patient were colitis (1.4%), autoimmune hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and cardiac failure (0.4%). Adverse reactions leading to interruption of KEYTRUDA® occurred in 21% of patients; the most common (\geq 1%) was diarrhea (2.5%). The most common adverse reactions (reported in at least 20% of patients) were fatigue and diarrhea.

There were no new safety signals observed at the final analysis. After 9 additional months of follow-up from the second interim analysis to final analysis, no meaningful changes occurred in the safety profile of pembrolizumab.

Table 2: Treatment-Related Adverse Events (incidence ≥ 1%) KEYTRUDA® Treatment Groups Combined, All patients as treated (APaT) Population in KEYNOTE 006.

	KE 10 mg/kg e	YTRUDA ^c every 2 or 3 n=555		Ipilimumab 3 mg/kg every 3 weeks n=256		
Adverse Reaction	Any Grade n (%)	Grade 3 n (%)	Grade 4 n (%)	Any Grade n (%)	Grade 3 n (%)	Grade 4 n (%)
Blood and lymphatic system disc	orders					
Anemia	9 (1.6)	2 (0.4)	0	1 (0.4)	1 (0.4)	0
Endocrine disorders						

	KEY	TRUDA	0	Ipilimumab			
	10 mg/kg e			_	g every 3 v n=256		
Adverse Reaction	Any	Grade	Grade	Any	Grade	Grade	
Traverse reaction	Grade	3	4	Grade	3	4	
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	
Hyperthyroidism	24 (4.3)	0	0	6 (2.3)	1 (0.4)	0	
Hypothyroidism	46 (8.3)	1 (0.2)	0	2 (0.8)	0	0	
Gastrointestinal disorders							
Abdominal pain	15 (2.7)	0	0	15 (5.9)	0	0	
Abdominal pain upper	7 (1.3)	0	0	1 (0.4)	0	0	
Colitis	12 (2.2)	7 (1.3)	2 (0.4)	19 (7.4)	14 (5.5)	2 (0.8)	
Constipation	12 (2.2)	0	0	5 (2.0)	0	0	
Diarrhea	87 (15.7)	10 (1.8)	0	58 (22.7)	8 (3.1)	0	
Dry mouth	31 (5.6)	0	0	1 (0.4)	0	0	
Nausea	59 (10.6)	1 (0.2)	0	22 (8.6)	1 (0.4)	0	
Vomiting	15 (2.7)	1 (0.2)	0	14 (5.5)	0	0	
General disorders and administra	ation site con	ditions	II.		I	l .	
Asthenia	63 (11.4)	1 (0.2)	0	16 (6.3)	2 (0.8)	0	
Fatigue	111(20.0)	1 (0.2)	0	39 (15.2)	3 (1.2)	0	
Influenza like illness	8 (1.4)	0	0	4 (1.6)	1 (0.4)	0	
Pyrexia	14 (2.5)	0	0	6 (2.3)	0	0	
Injury, poisoning and procedural	complication	ns		, ,	1	ı	
Infusion related reaction	6 (1.1)	0	0	0	0	0	
Investigations							
Alanine aminotransferase	16 (2.9)	1 (0.2)	0	9 (3.5)	1 (0.4)	1 (0.4)	
increased							
Aspartate aminotransferase	20 (3.6)	0	1 (0.2)	6 (2.3)	2 (0.8)	0	
increased							
Blood bilirubin increased	7 (1.3)	0	0	0	0	0	
Blood creatinine increased	7 (1.3)	0	0	1 (0.4)	0	0	
Blood thyroid stimulating	6 (1.1)	0	0	2 (0.8)	1 (0.4)	0	
hormone decreased							
Weight decreased	6 (1.1)			5 (2.0)	1 (0.4)	0	
Metabolism and nutrition disord		1	T	ı	1	П	
Decreased appetite	35 (6.3)	0	0	20 (7.8)	0	0	
Hypocalcemia	8 (1.4)	0	0	0	0	0	
Musculoskeletal and connective t		1	I	Ti .			
Arthralgia	58 (10.5)	1 (0.2)	0	13 (5.1)	2 (0.8)	0	
Arthritis	6 (1.1)	0	0	0	0	0	
Back pain	12 (2.2)	0	0	0 (0.0)	0	0	
Muscle spasms	7 (1.3)	0	0	1 (0.4)	0	0	
Myalgia	25 (4.5)	1 (0.2)	0	5 (2.0)	1 (0.4)	0	
Pain in extremity	7 (1.3)	2 (0.4)	0	1 (0.4)	0	0	
Nervous system disorders							

		TRUDA		_	ilimumab	
	10 mg/kg ev	very 2 or : n=555	3 weeks	3 mg/kg	g every 3 v n=256	veeks
Adverse Reaction	Any	Grade	Grade	Any	Grade	Grade
Auverse Reaction	Grade	3	4	Grade	3	4
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Dizziness	9 (1.6)	0	0	2 (0.8)	0	0
Dysgeusia	15 (2.7)	0	0	3 (1.2)	0	0
Headache	15 (2.7)	0	0	9 (3.5)	0	0
Psychiatric disorders		l	I.		1	I.
Insomnia	7 (1.3)	0	0	0	0	0
Respiratory, thoracic and medias	tinal disorde	rs				
Cough	22 (4.0)	0	0	0	0	0
Dyspnea	12 (2.2)	1 (0.2)	0	3 (1.2)	1 (0.4)	0
Skin and subcutaneous tissue disc	orders					
Dry skin	14 (2.5)	0	0	3 (1.2)	0	0
Eczema	7 (1.3)	0	0	1 (0.4)	0	0
Erythema	11 (2.0)	0	0	5 (2.0)	0	0
Hair colour changes	6 (1.1)	0	0	0	0	0
Papule	6 (1.1)	0	0	0	0	0
Pruritus	79 (14.2)	0	0	65 (25.4)	1 (0.4)	0
Rash	78 (14.1)	0	0	37 (14.5)	1 (0.4)	1 (0.4)
Rash maculo-papular	16 (2.9)	1 (0.2)	0	7 (2.7)	1 (0.4)	0
Rash pruritic	7 (1.3)	0	0	4 (1.6)	0	0
Skin hypopigmentation	9 (1.6)	0	0	0	0	0
Vitiligo	56 (10.1)	0	0	4 (1.6)	0	0
Vascular disorders						
Flushing	6 (1.1)	0	0	2 (0.8)	0	0

Treatment-related adverse events reported in <1% patients with melanoma treated with KEYTRUDA $^{\text{@}}$ 10 mg/kg every 2 or 3 weeks (n=555) by system organ class (SOC) are shown below.

Endocrine disorders: adrenal insufficiency, hypophysitis, hypopituitarism

Eye disorders: uveitis

Gastrointestinal disorders: pancreatitis Hepatobiliary disorders: hepatitis

Metabolism and nutrition disorders: Type 1 diabetes mellitus Musculoskeletal and connective tissue disorders: myositis

Nervous system disorders: Guillain-Barré syndrome

Respiratory, thoracic and mediastinal disorders: pneumonitis

Table 3: Treatment-Related Adverse Events (incidence ≥ 1%) KEYTRUDA® Treatment Groups Combined, APaT Population in KEYNOTE 002.

Adverse Reaction Blood and lymphatic system di	Any Grade n (%)	n=357 Grade 3 n (%)	Grade 4	Any Grade	n=171 Grade	- C - 1
Blood and lymphatic system di Anemia	Grade n (%) isorders	3	4	•	Grade	Ω 1
Blood and lymphatic system di Anemia	n (%) isorders	_	-	Crodo		Grade
Blood and lymphatic system di Anemia	isorders	n (%)	(0/)	Grade	3	4
Anemia		<u> </u>	n (%)	n (%)	n (%)	n (%)
	12 (3.4)					
Ear and labyrinth disorders		1 (0.3)	0	35 (20.5)	9 (5.3)	0
Vertigo	5 (1.4)	0	0	2 (1.2)	0	0
Endocrine disorders						
Hyperthyroidism	8 (2.2)	0	0	0	0	0
Hypothyroidism	22 (6.2)	0	0	0	0	0
Gastrointestinal disorders						
1	10 (2.8)	1 (0.3)	0	4 (2.3)	0	0
	4 (1.1)	2 (0.6)	0	0		0
Constipation	14 (3.9)	0	0	14 (8.2)	0	0
Diarrhea	34 (9.5)	2 (0.6)	0	14(8.2)	3 (1.8)	0
Dry mouth	6 (1.7)	0	0	0	0	0
Nausea	24 (6.7)	1 (0.3)	0	56 (32.7)	3 (1.8)	1 (0.6)
Vomiting	12 (3.4)	2 (0.6)	0	26 (15.2)	3 (1.8)	1 (0.6)
General disorders and adminis	stration sit	e conditio	ns			
Asthenia	14 (3.9)	2 (0.6)	0	10 (5.8)	1 (0.6)	0
Chills 11	1 (3.1)	0	0	6 (3.5)	0	0
Fatigue 9	92 (25.8)	3 (0.8)	0	62 (36.3)	8 (4.7)	0
Influenza like illness	9 (2.5)	0	0	1 (0.6)	0	0
Malaise	4 (1.1)	0	0	1 (0.6)	0	0
Edema peripheral	8 (2.2)	0	0	4 (2.3)	0	0
Pyrexia	17 (4.8)	0	0	8 (4.7)	1 (0.6)	0
Investigations						
Alanine aminotransferase increased	11 (3.1)	1 (0.3)	0	3 (1.8)	0	0
Aspartate aminotransferase increased	10 (2.8)	2 (0.6)	0	0	0	0
Blood alkaline phosphatase increased	6 (1.7)	0	0	0	0	0
	4 (1.1)	0	0	3 (1.8)	0	0
	4 (1.1)	1 (0.3)	0	7 (4.1)	2 (1.2)	0
Metabolism and nutrition disor	rders					
	25 (7.0)	2 (0.6)	0	26 (15.2)	0	0
Musculoskeletal and connective	, ,	` /		_= (10.2)		
	25 (7.0)	2 (0.6)	0	9 (5.3)	1 (0.6)	0
	5 (1.4)	0	0	2 (1.2)	1 (0.6)	0

	KEY 2 or 10 mg			Che	emothera	ру
		n=357			n=171	
Adverse Reaction	Any	Grade	Grade	Any	Grade	Grade
	Grade	3	4	Grade	3	4
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Joint stiffness	4 (1.1)	0	0	1 (0.6)	0	0
Myalgia	16 (4.5)	2 (0.6)	0	10 (5.8)	1 (0.6)	0
Pain in extremity	4 (1.1)	0	0	3 (1.8)	0	0
Nervous system disorders						
Dysgeusia	4 (1.1)	0	0	7 (4.1)	0	0
Headache	12 (3.4)	0	0	6 (3.5)	0	0
Respiratory, thoracic and m	nediastinal di	sorders				
Cough	12 (3.4)	0	0	1 (0.6)	0	0
Dyspnea	12 (3.4)	0	1 (0.3)	4 (2.3)	0	0
Pneumonitis	4 (1.1)	2 (0.6)	0	0	0	0
Skin and subcutaneous tissu	ie disorders					
Alopecia	6 (1.7)	0	0	35 (20.5)	1 (0.6)	0
Dermatitis acneiform	4 (1.1)	0	0	0	0	0
Dry skin	18 (5.0)	0	0	2 (1.2)	0	0
Eczema	7 (2.0)	0	0	0	0	0
Erythema	4 (1.1)	0	0	4 (2.3)	0	0
Hyperhidrosis	4 (1.1)	0	0	2 (1.2)	0	0
Pruritus	79 (22.1)	0	0	6 (3.5)	0	0
Rash	39 (10.9)	0	0	8 (4.7)	0	0
Rash generalized	4 (1.1)	0	0	1 (0.6)	0	0
Rash maculo-papular	15 (4.2)	2 (0.6)	0	0	0	0
Skin hypopigmentation	6 (1.7)	0	0	0	0	0
Vitiligo	19 (5.3)	0	0	2 (1.2)	0	0

Treatment-related adverse events reported in <1% patients with melanoma treated with KEYTRUDA® 2 mg/kg or 10 mg/kg every 3 weeks (n=357) by SOC are shown below.

Blood and lymphatic system disorders: hemolytic anemia **Endocrine disorders:** hypophysitis, hypopituitarism

Eve disorders: uveitis

Gastrointestinal disorders: pancreatitis Hepatobiliary disorders: hepatitis

Musculoskeletal and connective tissue disorders: arthritis

Overall, the safety profile was similar across all doses and between patients previously treated with ipilimumab and patients naïve to treatment with ipilimumab.

NSCLC

Table 4 summarizes the treatment-related adverse events that occurred in at least 1% of patients with NSCLC treated with KEYTRUDA® in KEYNOTE-024. The most common treatment-related adverse events (reported in at least 10% of patients) were diarrhea, fatigue, and pyrexia. The most common Grade 3-5 treatment-related adverse events for patients treated with KEYTRUDA® in KEYNOTE-024 were diarrhea (3.9%), pneumonitis (2.6%), and anemia (1.9%).

Treatment was discontinued for treatment related adverse events in 7.1% of the 154 patients receiving KEYTRUDA® and in 10.7% of the 150 patients receiving chemotherapy. The most common treatment-related adverse event leading to study drug discontinuation (occurring in more than 2 patients) was: pneumonitis (n=6). The median time to discontinuation for treatment-related adverse events was 0.7 months. There were 9 (5.8%) deaths reported in the KEYTRUDA® arm: pneumonia (n=2), respiratory failure (n=2), cardiac arrest (n=1), hemorrhagic stroke (n=1), sepsis (n=1), general physical health deterioration (n=1), and sudden death (n=1). One of the deaths (sudden death) was considered by the investigator to be related to treatment. There were 7 (4.7%) death in the chemotherapy arm; cardiac arrest/failure (n=3), sepsis (n=1), pulmonary embolism (n=1), pulmonary alveolar hemorrhage (n=1) and not specified (n=1). Three of the deaths (sepsis, pulmonary alveolar hemorrhage, and not specified) were considered to be treatment related.

Table 4: Treatment-Related Adverse Events (incidence ≥ 1%) in Patients Treated with KEYTRUDA®, APaT Population in KEYNOTE 024

KETIKODI ,II		TRUDA®			emotherap	y
	200 mg e	very 3 wo	eeks			
	n	=154			n=150	
Adverse Reaction	Any Grade n (%)	Grade 3 n (%)	Grade 4 n (%)	Any Grade n (%)	Grade 3 n (%)	Grade 4 n (%)
Blood and lymphatic syste	m disorders	11 (70)	11 (70)	11 (70)		11 (70)
Anemia	8 (5.2)	3 (1.9)	0	66 (44.0)	29 (19.3)	0
Eosinophilia	3 (1.9)	0	0	0	0	0
Lymphopenia	2 (1.3)	0	0	0	0	0
Endocrine disorders						
Hyperthyroidism	11 (7.1)	0	0	0	0	0
Hypothyroidism	12 (7.8)	0	0	1 (0.7)	0	0
Thyroiditis	3 (1.9)	0	0	0	0	0
Gastrointestinal disorders						
Abdominal pain	4 (2.6)	0	0	3 (2.0)	0	0
Abdominal distention	2 (1.3)	0	0	0	0	0
Colitis	2 (1.3)	2 (1.3)	0	0	0	0
Constipation	6 (3.9)	0	0	17 (11.3)	0	0
Diarrhea	22(14.3)	6 (3.9)	0	20 (13.3)	2 (1.3)	0
Dyspepsia	2 (1.3)	0	0	4 (2.7)	0	0
Nausea	15 (9.7)	0	0	65 (43.3)	3 (2.0)	0
Stomatitis	4 (2.6)	0	0	18 (12.0)	2 (1.3)	0

KEYTRUDA [®]				Ch	emotherap	v		
	200 mg e				F	J		
	0	=154			n=150			
Adverse Reaction		Grade	Grade	Any		Grade		
	Any Grade	3	4	Grade	Grade 3	4		
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)		
Vomiting	4 (2.6)	1 (0.6)	0	30 (20.0)	1(0.7)	0		
General disorders and administration site conditions								
Asthenia	5 (3.2)	1 (0.6)	0	11 (7.3)	2 (1.3)	0		
Chills	3 (1.9)	0	0	0	0	0		
Fatigue	16 (10.4)	2 (1.3)	0	43 (28.7)	5 (3.3)	0		
Edema	2 (1.3)	0	0	2 (1.3)	0	0		
Edema peripheral	4 (2.6)	1 (0.6)	0	6 (4.0)	0	0		
Pyrexia	16 (10.4)	0	0	8 (5.3)	0	0		
Lower respiratory tract	2 (1.3)	2 (1.3)						
infection								
Infusion related reaction	3 (1.9)	0	0	0	0	0		
Investigations				_				
Alanine aminotransferase	10 (6.5)	0	0	7 (4.7)	0	0		
increased								
Aspartate	8 (5.2)	2 (1.3)	0	5 (3.3)	0	0		
aminotransferase increased								
Blood creatinine increased	3 (1.9)	0	0	15 (10.0)	1 (0.7)	0		
Blood thyroid stimulating	5 (3.2)	0	0	0	0	0		
hormone increased								
Blood thyroid stimulating hormone decreased	4 (2.6)	0	0	0	0	0		
Gamma-	3 (1.9)	1 (0.6)	0	4 (2.7)	0	0		
glutamyltransferase	3 (1.7)	1 (0.0)		1 (2.7)				
increased								
Hepatic enzyme increased	2 (1.3)	1 (0.6)	0	0	0	0		
Transaminase increased	3 (1.9)	2 (1.3)	0	0	0	0		
Weight decreased	5 (3.2)	0	0	4 (2.7)	0	0		
Metabolism and nutrition	disorders	'				'		
Decreased appetite	14 (9.1)	0	0	39 (26.0)	4 (2.7)	0		
Diabetes Mellitus	2 (1.3)	2 (1.3)	0	0	0	0		
Hyperglycemia	2 (1.3)	0	1 (0.6)	2 (1.3)	0	0		
Hyperkalemia	3 (1.9)	0	0	1 (0.7)	0	0		
Hypoalbumineamea	3 (1.9)	2 (1.3)	0	4 (2.7)	2 (1.3)	0		
Hyponatremia	5 (3.2)	0	0	2 (1.3)	1 (0.7)	0		
Musculoskeletal and conne	ective tissue di	sorders						
Arthralgia	13 (8.4)	0	0	4 (2.7)	0	0		
Arthritis	2 (1.3)	0	0	0	0	0		
Back pain	2 (1.3)	0	0	1 (0.7)	0	0		
Myalgia	3 (1.9)	0	0	1 (0.7)	0	0		

	KEY	TRUDA®)	Chemotherapy			
	200 mg e	very 3 w	eeks				
	n	=154			n=150		
Adverse Reaction	Any Grade n (%)	Grade 3 n (%)	Grade 4 n (%)	Any Grade n (%)	Grade 3 n (%)	Grade 4 n (%)	
Nervous system disorders							
Dizziness	2 (1.3)	0	0	3 (2.0)	0	0	
Neuropathy peripheral	2 (1.3)	0	0	9 (6.0)	1 (0.7)	0	
Paresthesia	2 (1.3)	0	0	2 (1.3)	0	0	
Renal and urinary disorde	rs						
Dysuria	2 (1.3)	0	0	1 (0.7)	0	0	
Respiratory, thoracic and	mediastinal di	sorders					
Cough	5 (3.2)	0	0	0	0	0	
Dyspnea	4 (2.6)	1 (0.6)	0	5 (3.3)	1 (0.7)	0	
Hiccups	2 (1.3)	0	0	7 (4.7)	0	0	
Pneumonitis	8 (5.2)	2 (1.3)	2 (1.3)	1 (0.7)	1 (0.7)	0	
Skin and subcutaneous tiss	sue disorders						
Dry skin	8 (5.2)	0	0	1 (0.7)	0	0	
Erythema	3 (1.9)	0	0	0	0	0	
Night sweats	3 (1.9)	0	0	0	0	0	
Pruritus	12 (7.8)	0	0	3 (2.0)	0	0	
Pruritus generalized	3 (1.9)	0	0	1 (0.7)	0	0	
Psoriasis	2 (1.3)	1 (0.6)	0	0	0	0	
Rash	11 (7.1)	1 (0.6)	0	3 (2.0)	0	0	
Rash maculo-papular	5 (3.2)	1 (0.6)	0	1 (0.7)	0	0	
Rash pruritic	2 (1.3)	0	0	1 (0.7)	0	0	
Skin exfoliation	2 (1.3)	0	0	0	0	0	
Urticaria	2 (1.3)	0	0	1 (0.7)	0	0	

Treatment-related adverse events reported in <1% patients with NSCLC treated with KEYTRUDA® 200 mg every 3 weeks (n=154) by SOC are shown below.

Endocrine disorders: hypophysitis **Gastrointestinal disorders:** pancreatitis

Metabolism and nutrition disorders: diabetic ketoacidosis Musculoskeletal and connective tissue disorders: myositis

Table 5 summarizes the treatment-related adverse events that occurred in at least 1% of patients with NSCLC treated with KEYTRUDA $^{\text{®}}$ in KEYNOTE-010. Clinically important adverse reactions occurring in patients receiving KEYTRUDA $^{\text{®}}$ were fatigue (25%), diarrhea (14%), asthenia (11%) and pyrexia (11%). The most common treatment-related adverse events (reported in at least 10% of patients) were fatigue, decreased appetite, rash, and nausea. The most common Grade 3-5 treatment-related adverse events for patients treated with KEYTRUDA $^{\text{®}}$ in KEYNOTE-010 were pneumonitis (1.8%) and fatigue (1.5%).

In KEYNOTE-010, the adverse reaction profile was similar for the 2 mg/kg and 10 mg/kg dose, therefore summary safety results are provided in a pooled analysis (n=682). Treatment was discontinued for treatment-related adverse events in 5% of patients receiving KEYTRUDA[®]. The most common treatment-related adverse event resulting in permanent discontinuation of KEYTRUDA[®] was pneumonitis (1.8%, n =12). The median time to discontinuation for treatment-related adverse events was 2.5 months. Treatment-related adverse events leading to interruption of KEYTRUDA[®] occurred in 13% of patients; the most common (\geq 1%) were fatigue (1.2%) and decreased appetite (1%).

Table 5: Treatment-Related Adverse Events (incidence ≥ 1%) KEYTRUDA® Treatment Groups Combined, APaT Population in KEYNOTE 010.

отокро у	KEYTRUDA® 2 or 10 mg/kg every 3 weeks n=682			75 r	Docet ng/m² evo n=3	ery 3 wee	eks	
Adverse Reaction	Any	Grade	Grade	Grade	Any	Grade	Grade	Grade
Auverse Reaction	Grade	3	4	5	Grade	3	4	5
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Blood and lymphatic			(, 0)	22 (70)	(/ 0 /	(, 0)	(, 0)	(/ 0 /
Anemia	24 (3.5)	4 (0.6)	0	0	40 (12.9)	5 (1.6)	0	0
Endocrine disorders					(''' /	I .		
Hyperthyroidism	25 (3.7)	1 (0.1)	0	0	0	0	0	0
Hypothyroidism	48 (7.0)	0	0	0	1 (0.3)	0	0	0
Eye disorders								
Dry eye	10 (1.5)	0	0	0	1 (0.3)	0	0	0
Gastrointestinal disor	rders							
Abdominal pain	7 (1.0)	0	0	0	4 (1.3)	0	0	0
Constipation	23 (3.4)	0	0	0	14 (4.5)	0	0	0
Diarrhea	46 (6.7)	2 (0.3)	0	0	56 (18.1)	6 (1.9)	1 (0.3)	0
Dry mouth	8 (1.2)	0	0	0	3 (1.0)	0	0	0
Nausea	68 (10.0)	3 (0.4)	0	0	45 (14.6)	1 (0.3)	0	0
Stomatitis	20 (2.9)	1 (0.1)	0	0	43 (13.9)	3 (1.0)	0	0
Vomiting	25 (3.7)	1 (0.1)	0	0	24 (7.8)	2 (0.6)	0	0
General disorders an			conditio	ns			ll .	
Asthenia	39 (5.7)	3 (0.4)	0	0	35 (11.3)	6 (1.9)	0	0
Fatigue	95(13.9)	10 (1.5)	0	0	76 (24.9)	11 (3.6)	0	0
Influenza like illness	7 (1.0)	0	0	0	0	0	0	0
Malaise	14 (2.1)	0	0	0	11 (3.6)	0	0	0
Edema peripheral	9 (1.3)	0	0	0	21 (6.8)	0	0	0
Pyrexia	24 (3.5)	1 (0.1)	0	0	17 (5.5)	1 (0.3)	0	0

		KEYTRU		nalra	75 ×	Docet		alea
	2 or 10	mg/kg ev n=68	•	eeks	/5 r	ng/m² evo n=3		eks
Adverse Reaction	Any	Grade	Grade	Grade	Any	Grade	Grade	Grade
	Grade	3	4	5	Grade	3	4	5
T C 4	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Infections and infesta		4 (0 6)	0	2 (0.2)	<i>5</i> (1.6)	2 (0 ()	2 (0 ()	0
Pneumonia	10 (1.5)	4 (0.6)	0	2 (0.3)	5 (1.6)	2 (0.6)	2 (0.6)	0
Investigations								
Alanine	24 (3.5)	3 (0.4)	0	0	4 (1.3)	0	0	0
aminotransferase								
increased	15 (2.5)	2 (0.2)	0	0	2 (1 0)	0	0	0
Aspartate	17 (2.5)	2 (0.3)	0	0	3 (1.0)	0	0	0
aminotransferase								
increased	11 (1 6)	2 (0.2)	0	0	2 (0 ()	0	0	0
Blood alkaline	11 (1.6)	2 (0.3)	0	0	2 (0.6)	0	0	0
phosphatase								
increased Blood creatinine	12 (1.0)	0	0	0	0	0	0	0
	13 (1.9)	0	0	U	0	0	0	0
increased Pland thyraid	7 (1 0)	0	0	0	0	0	0	0
Blood thyroid	7 (1.0)	U	U	U	U	U	U	U
stimulating hormone increased								
Weight decreased	15 (2.2)	1 (0.1)	0	0	2 (0.6)	0	0	0
Metabolism and nutr	\ /	` /	U	U	2 (0.0)	U	U	U
Decreased appetite	79 (11.6)	4 (0.6)	0	0	49	3 (1.0)	0	0
Decreased appende	77 (11.0)	4 (0.0)	U	U	(15.9)	3 (1.0)	U	U
Hypertriglyceridemia	10 (1.5)	2 (0.3)	2 (0.3)	0	0	0	0	0
Musculoskeletal and		, ,	\ /	U	U U	U	U	U
Arthralgia	32 (4.7)	2 (0.3)	0	0	18 (5.8)	0 (0.0)	0	0
Back pain	9 (1.3)	1 (0.1)	0	0	0	0	0	0
Musculoskeletal pain	8 (1.2)	0	0	0	4 (1.3)	0	0	0
Myalgia	19 (2.8)	0	0	0	29 (9.4)	0	0	0
Nervous system disor					(>••)	J		<u> </u>
Dizziness	11 (1.6)	0	0	0	5 (1.6)	1 (0.3)	0	0
Dysgeusia	11 (1.6)	0	0	0	16 (5.2)	0	0	0
Headache	14 (2.1)	0	0	0	2 (0.6)	0	0	0
Respiratory, thoracic		_			_ (0.0)	J		<u> </u>
Cough	11 (1.6)	0	0	0	3 (1.0)	0	0	0
Dyspnea	21 (3.1)	4 (0.6)	0	0	13 (4.2)	4 (1.3)	0	0
Pneumonitis	26 (3.8)	5 (0.7)	4 (0.6)	3 (0.4)	3 (1.0)	1 (0.3)	0	0
Skin and subcutaneou	` '	` /	. (3.3)	1 - (3)	- (2.0)	- (5.5)		· · · · · ·
Dry skin	18 (2.6)	0	0	0	4 (1.3)	0	0	0
Pruritus	57 (8.4)	0	0	0	5 (1.6)	1 (0.3)	0	0
Rash	73 (10.7)	2 (0.3)	0	0	14 (4.5)	0	0	0

	KEYTRUDA® 2 or 10 mg/kg every 3 weeks n=682 Docetaxel 75 mg/m² every 3 weeks n=309			75 mg/m ² every 3 n=309			eks	
Adverse Reaction	Any Grade n (%)	Grade 3 n (%)	Grade 4 n (%)	Grade 5 n (%)	Any Grade n (%)	Grade 3 n (%)	Grade 4 n (%)	Grade 5 n (%)
Rash maculo-papular	9 (1.3)	1 (0.1)	0	0	0	0	0	0

Treatment-related adverse events reported in <1% patients with NSCLC treated with pembrolizumab 2 mg/kg or 10 mg/kg every 3 weeks (n=682) by SOC are shown below.

Endocrine disorders: hypopituitarism, adrenal insufficiency

Gastrointestinal disorders: colitis, pancreatitis

Injury, poisoning and procedural complications: infusion related reaction

Metabolism and nutrition disorders: diabetic ketoacidosis, Type 1 diabetes mellitus

Musculoskeletal and connective tissue disorders: arthritis Skin and subcutaneous tissue disorders: pemphigoid

Hodgkin Lymphoma

Table 6 summarizes the treatment-related adverse events that occurred in at least 1% of patients with Hodgkin Lymphoma treated with KEYTRUDA® in KEYNOTE-013 and 087. The most common adverse event (reported in at least 10% of patients) was hypothyroidism. Eleven percent of patients had \geq Grade 3 adverse events. The most common \geq Grade 3 adverse events (occurring in more than 2 patients) were: neutropenia (n=5, 2.1%) and dyspnea (n=3, 1.2%).

KEYTRUDA® was discontinued for treatment-related adverse events in 5% of patients with Hodgkin Lymphoma. The most common treatment-related adverse event leading to study drug discontinuation (occurring in more than 2 patients) was: pneumonitis (n=5, 2.1%). The median time to discontinuation for treatment-related adverse events was 1.5 months.

Table 6: Treatment-Related Adverse Events Occurring in ≥ 1% of Patients with Hodgkin Lymphoma treated with KEYTRUDA® in KEYNOTE-013 and KEYNOTE-087

	KEYTR	
	10 mg/kg every 2 wee	<u> </u>
	3 we	
	N=2	241
Adverse Event	Any Grade	Grade 3
	n (%)	n (%)
Blood and lymphatic system disorders		
Neutropenia	11 (4.6)	5 (2.1)
Thrombocytopenia	3 (1.2)	1 (0.4)
Cardiac disorders		
Palpitations	3 (1.2)	0
Endocrine disorders		
Hyperthyroidism	6 (2.5)	0
Hypothyroidism	30 (12.4)	1 (0.4)

	KEYTRUDA® 10 mg/kg every 2 weeks or 200 mg 3 weeks N=241		
Adverse Event	Any Grade n (%)	Grade 3 n (%)	
Gastrointestinal disorders	n (70)	H (70)	
Abdominal distension	3 (1.2)	0	
Abdominal pain	5 (2.1)	0	
Colitis	3 (1.2)	2 (0.8)	
Constipation	7 (2.9)	0	
Diarrhea	21 (8.7)	2 (0.8)	
Dry mouth	3 (1.2)	0	
Nausea	16 (6.6)	0	
Stomatitis	3 (1.2)	0	
Vomiting	10 (4.1)	0	
General disorders and administration sit	e conditions		
Asthenia	5 (2.1)	0	
Chest pain	4 (1.7)	0	
Chills	7 (2.9)	0	
Fatigue	22 (9.1)	1 (0.4)	
Pain	3 (1.2)	0	
Pyrexia	22 (9.1)	1 (0.4)	
Immune System Disorders			
Cytokine release syndrome	6 (2.5)	1 (0.4)	
Infections and infestations			
Oral herpes	3 (1.2)	0	
Upper respiratory tract infection	7 (2.9)	0	
Injury, poisoning and procedural compli	cations		
Infusion related reaction	10 (4.1)	0	
Investigations			
Alanine aminotransferase increased	4 (1.7)	0	
Aspartate aminotransferase increased	4 (1.7)	1 (0.4)	
Platelet count decreased	5 (2.1)	0	
Weight decreased	5 (2.1)	1 (0.4)	
Weight increased	3 (1.2)	0	
White blood cell count decreased	3 (1.2)	0	
Metabolism and nutrition disorders			
Decreased appetite	6 (2.5)	1 (0.4)	
Musculoskeletal and connective tissue dis	sorders		
Arthralgia	11 (4.6)	1 (0.4)	
Back pain	5 (2.1)	1 (0.4)	
Bone pain	4 (1.7)	1 (0.4)	
Muscle spasms	9 (3.7)	0	
Myalgia	6 (2.5)	0	

	10 mg/kg every 2 wee 3 we N=2	eks or 200 mg every eks
Adverse Event	Any Grade	Grade 3
	n (%)	n (%)
Nervous system disorders		
Headache	14 (5.8)	0
Respiratory, thoracic and mediastin	al disorders	
Cough	13 (5.4)	1 (0.4)
Dyspnea	10 (4.1)	3 (1.2)
Nasal congestion	3 (1.2)	0
Pneumonitis	10 (4.1)	0
Skin and subcutaneous tissue disord	lers	
Alopecia	4 (1.7)	0
Dry skin	7 (2.9)	0
Pruritus	9 (3.7)	0
Rash	16 (6.6)	0

Two deaths due to adverse events regardless of relationship to therapy were reported among the 241 patients with HL in KEYNOTE-013 and 087. Cause of death for these patients was graft versus host disease and septic shock.

Of 23 patients with cHL who proceeded to allogeneic HSCT after treatment with pembrolizumab, 6 patients (26%) developed GVHD, one of which was fatal, and 2 patients (9%) developed severe hepatic VOD after reduced-intensity conditioning, one of which was fatal. The 23 patients had a median follow-up from subsequent allogeneic HSCT of 5.1 months (range: 0-26.2 months).

Treatment related adverse events reported in <1% patients with HL treated with KEYTRUDA® 10 mg/kg every 2 weeks or 200 mg every 3 weeks (n=241) by SOC are shown below:

Musculoskeletal and connective tissue disorders: arthritis, myositis

Urothelial Carcinoma

Table 7 summarizes the treatment-related adverse events that occurred in at least 1% of patients with urothelial carcinoma treated with KEYTRUDA® in KEYNOTE-045. The most common treatment-related adverse events (reported in at least 10% of patients) were pruritus, fatigue and nausea. Fifteen percent of patients had \geq Grade 3 treatment-related adverse events. The most common \geq Grade 3 adverse reactions (occurring in more than 2 patients) were: pneumonitis (n=4), diarrhea (n=3), fatigue (n=3) and aspartate aminotransferase increase (n=3).

KEYTRUDA[®] was discontinued for treatment-related adverse events in 5.6% of patients in KEYNOTE 045. The most common treatment-related adverse event leading to study drug discontinuation (occurring in more than 2 patients) was: pneumonitis (n=5). The median time to discontinuation for treatment-related adverse events was 0.7 months.

Table 7: Treatment-Related Adverse Events Occurring in \geq 1% of Patients with Urothelial Carcinoma treated with KEYTRUDA® in KEYNOTE-045

Carcinoma treated with KEYTRUDA® in KEYNOTE-045 KEYTRUDA® Chemotherapy									
	• •				Chemotherapy				
	20	0 mg eve	•	KS		n=2	55		
		n=2		T			1	T	
Adverse Reaction	Any	Grade	Grade	Grade	Any	Grade	Grade	Grade	
	Grade	3	4	5	Grade	3	4	5	
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	
Blood and lymphat					T			ı	
Anemia	9 (3.4)	2 (0.8)	0(0)	0 (0)	63	20	0 (0)	0 (0)	
					(24.7)	(7.8)			
Endocrine disorder	1			r			1	1	
Hyperthyroidism	10 (3.8)	0 (0)	0(0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
Hypothyroidism	15 (5.6)	0 (0)	0(0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
Gastrointestinal dis	orders								
Abdominal pain	4 (1.5)	0 (0)	0 (0)	0 (0)	10 (3.9)	0 (0)	0 (0)	0 (0)	
Colitis	5 (1.9)	2 (0.8)	0 (0)	0 (0)	1 (0.4)	0 (0)	0 (0)	0 (0)	
Constipation	6 (2.3)	0 (0)	0 (0)	0 (0)	52	7 (2.7)	0 (0)	0 (0)	
	, ,	, ,		, ,	(20.4)	, ,	, ,	, ,	
Diarrhea	24 (9.0)	3 (1.1)	0 (0)	0 (0)	33	1 (0.4)	1 (0.4)	0 (0)	
	, ,	, ,	· /	, ,	(12.9)			. ,	
Dry mouth	4 (1.5)	0 (0)	0 (0)	0 (0)	2 (0.8)	0 (0)	0 (0)	0 (0)	
Flatulence	3 (1.1)	0 (0)	0 (0)	0 (0)	1 (0.4)	0 (0)	0 (0)	0 (0)	
Nausea	29	1 (0.4)	0 (0)	0 (0)	62	4 (1.6)	0 (0)	0 (0)	
	(10.9)	()	- (-)	- (-)	(24.3)	('-')	- (-)	- (-)	
Stomatitis	4 (1.5)	1 (0.4)	0 (0)	0 (0)	21 (8.2)	1 (0.4)	0 (0)	0 (0)	
Vomiting	12 (4.5)	0 (0)	0 (0)	0 (0)	25 (9.8)	1 (0.4)	0 (0)	0 (0)	
General disorders a	` '	\ /			(> 10)	- (***)	0 (0)	- (°)	
Asthenia	15 (5.6)	1 (0.4)	0 (0)	0 (0)	36	7 (2.7)	0 (0)	0 (0)	
	10 (0.0)	1 (01.)	0 (0)	0 (0)	(14.1)	, (=1,)	0 (0)	0 (0)	
Chills	3 (1.1)	0 (0)	0 (0)	0 (0)	4 (1.6)	0 (0)	0 (0)	0 (0)	
Fatigue	37	3 (1.1)	0 (0)	0 (0)	71	11	0 (0)	0 (0)	
	(13.9)	5 (1.1)	0 (0)	0 (0)	(27.8)	(4.3)	0 (0)	0 (0)	
Influenza like	3 (1.1)	0 (0)	0 (0)	0 (0)	3 (1.2)	0 (0)	0 (0)	0 (0)	
illness	3 (1.1)	0 (0)	0 (0)	0 (0)	3 (1.2)	0 (0)	0 (0)	0 (0)	
Malaise	4 (1.5)	0 (0)	0 (0)	0 (0)	8 (3.1)	0 (0)	0 (0)	0 (0)	
Mucosal	3 (1.1)	1 (0.4)	0 (0)	0 (0)	17 (6.7)	2 (0.8)	0 (0)	0 (0)	
inflammation	3 (1.1)	1 (0.4)	0 (0)		17 (0.7)	2 (0.0)	0 (0)		
Pyrexia	17 (6.4)	0 (0)	0 (0)	0 (0)	8 (3.1)	1 (0.4)	0 (0)	0 (0)	
Infections and infes	` /	0 (0)	0 (0)	U (U)	0 (3.1)	1 (0.4)	0 (0)	0 (0)	
Urinary Tract	3 (1.1)	0 (0)	0 (0)	0 (0)	8 (3.1)	3 (1.2)	1 (0.4)	0 (0)	
Infection	3 (1.1)	0 (0)	0 (0)	0 (0)	0 (3.1)	3 (1.4)	1 (0.4)	0 (0)	
Investigations									
	0 (2.4)	2 (0.9)	0 (0)	0 (0)	2 (1.2)	0 (0)	0 (0)	0 (0)	
Alanine	9 (3.4)	2 (0.8)	0 (0)	0 (0)	3 (1.2)	0 (0)	0 (0)	0(0)	

		KEYTE	PIIDA®			Chemot	harany	
	20	0 mg eve		76		n=2		
	20	o mg ever n=2	•	79		11-2		
Adverse Reaction	Any	Grade	Grade	Grade	Any	Grade	Grade	Grade
	Grade	3	4	5	Grade	3	4	5
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
aminotransferase						,		
increased								
Aspartate	7 (2.6)	3 (1.1)	0 (0)	0 (0)	2 (0.8)	0 (0)	0 (0)	0 (0)
aminotransferase	, ,	, ,	. ,	. ,	` ′	. ,		, ,
increased								
Blood alkaline	3 (1.1)	1 (0.4)	0 (0)	0 (0)	1 (0.4)	0 (0)	0 (0)	0 (0)
phosphatase								
increased								
Blood thyroid	3 (1.1)	0 (0)	0 (0)	0 (0)	0 (0.0)	0 (0.0)	0 (0)	0 (0)
stimulating								
hormone increased								
Gamma-	3 (1.1)	2 (0.8)	0(0)	0 (0)	1 (0.4)	0 (0)	0 (0)	0 (0)
glutamyltransferase								
increased								
Platelet count	3 (1.1)	1 (0.4)	0 (0)	0 (0)	7 (2.7)	2 (0.8)	1 (0.4)	0 (0)
decreased								
Weight decreased	4 (1.5)	0 (0)	0(0)	0 (0)	8 (3.1)	0 (0)	0 (0)	0 (0)
Metabolism and nu	1	orders	<u> </u>	1	T	T	Т	
Decreased appetite	23 (8.6)	0 (0)	0 (0)	0 (0)	41	3 (1.2)	0 (0)	0 (0)
					(16.1)			
Hyperglycemia	3 (1.1)	1 (0.4)	0 (0)	0 (0)	0 (0.0)	0 (0.0)	0 (0)	0 (0)
Musculoskeletal and				1	T	T		
Arthralgia	8 (3.0)	0 (0)	0 (0)	0 (0)	17 (6.7)	0 (0)	0 (0)	0 (0)
Back pain	3 (1.1)	0 (0)	0 (0)	0 (0)	2 (0.8)	0 (0)	0 (0)	0 (0)
Muscle spasms	3 (1.1)	0 (0)	0 (0)	0 (0)	1 (0.4)	0 (0)	0 (0)	0 (0)
Musculoskeletal	3 (1.1)	0 (0)	0 (0)	0 (0)	0 (0.0)	0 (0.0)	0 (0)	0 (0)
chest pain								
Myalgia	8 (3.0)	1 (0.4)	0 (0)	0 (0)	12 (4.7)	0 (0)	0 (0)	0 (0)
Pain in extremity	3 (1.1)	0 (0)	0 (0)	0 (0)	13 (5.1)	1 (0.4)	0 (0)	0 (0)
Nervous system disc					T =:			
Dizziness	6 (2.3)	0 (0)	0 (0)	0 (0)	7 (2.7)	1 (0.4)	0 (0)	0 (0)
Dysgeusia	3 (1.1)	0 (0)	0 (0)	0 (0)	14 (5.5)	0 (0)	0 (0)	0 (0)
Headache	4 (1.5)	1 (0.4)	0 (0)	0 (0)	8 (3.1)	0 (0)	0 (0)	0 (0)
Psychiatric disorder					T =			
Insomnia	3 (1.1)	0 (0)	0 (0)	0 (0)	5 (2.0)	0 (0)	0 (0)	0 (0)
Respiratory, thorac				1	2 (2.2)	0.75	0.75	0.40
Cough	7 (2.6)	0 (0)	0 (0)	0 (0)	2 (0.8)	0 (0)	0 (0)	0 (0)
Dyspnea	7 (2.6)	0 (0)	0 (0)	0 (0)	6 (2.4)	1 (0.4)	0 (0)	0 (0)
Dyspnoea	5 (1.9)	0 (0)	0(0)	0 (0)	4 (1.6)	0 (0)	0 (0)	0 (0)

	20	KEYTRUDA® 200 mg every 3 weeks n=266			Chemotherapy n=255			
Adverse Reaction	Any Grade n (%)	Grade 3 n (%)	Grade 4 n (%)	Grade 5 n (%)	Any Grade n (%)	Grade 3 n (%)	Grade 4 n (%)	Grade 5 n (%)
exertional	11 (70)	11 (70)	11 (70)	11 (70)	11 (70)	1 (70)	11 (70)	11 (70)
Pneumonitis	9 (3.4)	3 (1.1)	0 (0)	1 (0.4)	0 (0.0)	0 (0.0)	0 (0)	0 (0)
Skin and subcutane	eous tissue	disorder	S					
Dermatitis acneiform	3 (1.1)	0 (0)	0 (0)	0 (0)	2 (0.8)	0 (0)	0 (0)	0 (0)
Dry skin	6 (2.3)	0 (0)	0 (0)	0 (0)	7 (2.7)	0 (0)	0 (0)	0 (0)
Erythema	4 (1.5)	0 (0)	0 (0)	0 (0)	5 (2.0)	0 (0)	0 (0)	0 (0)
Pruritus	52 (19.5)	0 (0)	0 (0)	0 (0)	7 (2.7)	1 (0.4)	0 (0)	0 (0)
Rash	22 (8.3)	1 (0.4)	0 (0)	0 (0)	9 (3.5)	0 (0)	0 (0)	0 (0)
Rash maculo- papular	6 (2.3)	0 (0)	0 (0)	0 (0)	2 (0.8)	0 (0)	0 (0)	0 (0)
Urticaria	5 (1.9)	0 (0)	0 (0)	0 (0)	1 (0.4)	0 (0)	0 (0)	0 (0)
Vascular Disorders	1				•			
Hypertension	3 (1.1)	1 (0.4)	0 (0)	0 (0)	1 (0.4)	0 (0)	0 (0)	0 (0)

Treatment related adverse events reported in <1% patients with urothelial carcinoma treated with KEYTRUDA[®] 200 mg every 3 weeks (n=266) in KEYNOTE-045 by SOC are shown below:

Injury, poisoning and procedural complications: infusion related reaction

Musculoskeletal and connective tissue disorders: arthritis Renal and urinary disorders: nephritis, acute renal injury

Blood and lymphatic system disorders: thrombocytopenia, eosinophilia

Endocrine disorders: adrenal insufficiency, thyroiditis

Abnormal Hematologic and Clinical Chemistry Findings

Melanoma

Laboratory abnormalities (worsened from baseline in \geq 10% of patients), reported in KEYNOTE-006 in patients with advanced melanoma are presented in Table 8.

Table 8: Laboratory Abnormalities Worsened from Baseline in ≥10% of Patients with Unresectable or Metastatic Melanoma Treated with KEYTRUDA® and at a Higher Incidence than in the Ipilimumab Arm (Between Arm Difference of ≥5%)

[All Grades] or $\geq 2\%$ [Grades 3-4]) (KEYNOTE-006)

	KEYTI 10 mg/kg e wed n=5	very 2 or 3 eks	_	numab :256			
Laboratory Test	All Grades (%)	Grades 3-4 (%)	All Grades (%)	Grades 3-4 (%)			
Hematology				l			
Lymphopenia	33	6	25	6			
Leukopenia	12	0	5	0			
Thrombocytopenia	11	1	6	1			
Chemistry							
Hypertriglyceridemia	42	3	33	1			
Hypercholesterolemia	22	1	17	0			

Laboratory abnormalities (worsened from baseline in \geq 10% of patients), reported in KEYNOTE-002 in patients with advanced melanoma are presented in Table 9.

Table 9: Laboratory Abnormalities Worsened from Baseline in ≥10% of Patients with Unresectable or Metastatic Melanoma Treated with KEYTRUDA[®] and at a Higher Incidence than in the Chemotherapy Arm (Between Arm Difference of ≥5% [All Grades] or ≥ 2% [Grades 3-4]) (KEYNOTE-002)

	2 or 10 mg	KEYTRUDA® 2 or 10 mg/kg every 3 weeks		otherapy
		357	n=	:171
Laboratory Test	All Grades	Grades 3-4	All Grades	Grades 3-4
Chemistry				
Hyperglycemia	48	6	42	6
Hypoalbuminemia	35	2	30	1
Hyponatremia	36	7	24	4
Increased Alkaline Phosphatase	26	3	17	2
Increased Aspartate Aminotransferase	23	2	16	1
Hypercholesterolemia	20	1	11	0
Increased Alanine Aminotransferase	20	2	15	1
Bicarbonate decreased	18	0	10	0

Hyperkalemia	15	1	8	1
Creatinine increased	14	1	9	1

NSCLC

Laboratory abnormalities (worsened from baseline in \geq 10% of patients), reported in KEYNOTE-024 in patients with NSCLC, are presented in Table 10.

Table 10: Laboratory Abnormalities Worsened from Baseline in \geq 10% of Patients with NSCLC Treated with KEYTRUDA® and at a Higher Incidence than in the Chemotherapy Arm (Between Arm Difference of \geq 5% [All Grades] or \geq 2%

[Grades 3-4]), APaT population in KEYNOTE 024

[=],, - = [KEYTRUDA® Chemotherapy								
	KEYTI	RUDA	Chemotherapy						
	200 mg eve	ery 3 weeks							
	n =1	154	n=	:150					
I ab and Army Track	All Grades	Grades 3-4	All Grades	Grades 3-4					
Laboratory Test	%	%	%	%					
Chemistry									
Glucose Increased	80 (51.9)	12 (7.8)	69 (46.0)	9 (6.0)					
Alanine Aminotransferase	47 (30.5)	7 (4.5)	46 (30.7)	0					
Increased									
Calcium Decreased	39 (25.3)	0	30 (20.0)	0					
Aspartate Aminotransferase	38 (24.7)	6 (3.9)	49 (32.7)	0					
Increased									
Alkaline Phosphatase	34 (22.1)	4 (2.6)	36 (24.0)	0					
Increased		·							

Laboratory abnormalities (worsened from baseline in \geq 10% of patients), reported in KEYNOTE-010, in patients with NSCLC, are presented in Table 11. Patients were treated with pembrolizumab at 2 mg/kg or 10 mg/kg every 3 weeks.

Table 11: Laboratory Abnormalities Worsened from Baseline in \geq 10% of Patients with NSCLC Treated with KEYTRUDA® and at a Higher Incidence than in the Docetaxel Arm (Between Arm Difference of \geq 5% [All Grades] or \geq 2% [Grades 3-4]) (KEYNOTE-010)

	KEYTRUDA® 2 or 10 mg/kg every 3 weeks n=682		Docetaxel 75 mg/m ² every 3 weeks n=309	
Laboratory Test	All Grades	Grades 3- 4 (%)	All Grades (%)	Grades 3-4 (%)
Chemistry				
Hyponatremia	31	8	25	3
Increased alkaline phosphatase	28	3	16	0.6
Increased aspartate aminotransferase	25	2	12	0.6
Alanine aminotransferase increased	21	2	9	0.3
Hypomagnesia	19	0.3	13	0.3
Creatinine increased	18	0.9	9	0.6

Hodgkin Lymphoma

Laboratory abnormalities (worsened from baseline in $\geq 20\%$ of patients), reported in KEYNOTE-013 and KEYNOTE-087 in patients with Hodgkin Lymphoma are presented in Table 12.

Table 12: Laboratory Abnormalities Increased from Baseline in $\geq 20\%$ of Patients with Hodakin Lymphoma

Hodgkin Lymphoma			
	KEYTRUDA [®]		
	10 mg/kg every 2 we	eeks or 200 mg every	
	3 weeks n=241		
Laboratory Test	All Grades	Grades 3-4	
	%	%	
Alanine Aminotransferase Increased	58 (24.1)	9 (3.7)	
Aspartate aminotransferase Increased	61 (25.3)	3 (1.2)	
Glucose Decreased	59 (24.5)	3 (1.2)	
Glucose Increased	101 (41.9)	5 (2.1)	
Hemoglobin Decreased	68 (28.2)	15 (6.2)	
Leukocytes Decreased	63 (26.1)	6 (2.5)	
Lymphocytes Decreased	72 (29.9)	25 (10.4)	
Neurophils Decreased	61 (25.3)	19 (7.9)	
Phosphate Decreased	54 (22.4)	13 (5.4)	
Platelet Decreased	66 (27.4)	9 (3.7)	
Sodium Decreased	62 (25.7)	6 (2.5)	

Urothelial Carcinoma

Laboratory abnormalities (worsened from baseline in $\geq 10\%$ of patients), reported in KEYNOTE-045 in patients with urothelial carcinoma are presented in Table 13.

Table 13: Laboratory Abnormalities Worsened from Baseline in ≥10% of Patients with Urothelial Carcinoma treated with KEYTRUDA® and at a Higher Incidence than in the Chemotherapy Arm (Between Arm Difference of ≥5% [All Grades]

or > 2% [Crodes 3-4]) (KEVNOTE-045)

	KEYTRUDA® 200 mg every 3 weeks n=266		Chemotherapy n=255		
Laboratory Test	All Grades (%)	Grades 3-4 (%)	All Grades (%)	Grades 3-4 (%)	
Chemistry					
Alkaline Phosphatase Increased	35.4	7.2	32.2	4.7	

Aspartate Aminotransferase Increased	26	3.8	19.6	2.4
Creatinine Increased	34.9	4.1	27.4	3.1

The most frequently (\geq 20%) reported laboratory values that showed clinically meaningful worsening in CTCAE grade from baseline on the pembrolizumab arm were lymphocytes decreased and phosphate decreased. The incidence in the pembrolizumab arm was lower than in the control arm (lymphocytes decreased: 25.6% with pembrolizumab vs 34.9% with chemotherapy; phosphate decreased: 23.7% with pembrolizumab vs 27.5% with chemotherapy). The most frequent liver function test elevation by predetermined normal limit cutoffs was alkaline phosphatase (31.6%), a rate only slightly higher than the chemotherapy control group (28.5%).

Immunogenicity

As with all therapeutic proteins, there is the potential for immunogenicity. Trough levels of pembrolizumab interfere with the electrochemiluminescent (ECL) assay results; therefore, a subset analysis was performed in the patients with a concentration of pembrolizumab below the drug tolerance level of the anti-product antibody assay. In clinical studies in patients treated with pembrolizumab at a dose of 2 mg/kg every three weeks, 200 mg every three weeks, or 10 mg/kg every two or three weeks, 36 (1.8%) of 2034 evaluable patients tested positive for treatment-emergent antibodies against pembrolizumab during treatment with KEYTRUDA[®] of which 9 (0.4%) patients had neutralizing antibodies against pembrolizumab. There was no evidence of an altered pharmacokinetic or safety profile with anti-pembrolizumab binding or neutralizing antibody development.

The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of incidence of antibodies to KEYTRUDA® with the incidences of antibodies to other products may be misleading.

NOC/c DRUG INTERACTIONS

Overview

No formal pharmacokinetic drug interaction studies have been conducted with KEYTRUDA[®]. Since pembrolizumab is cleared from the circulation through catabolism, no metabolic drug-drug interactions are expected.

The use of systemic corticosteroids or immunosuppressants before starting KEYTRUDA® should be avoided because of their potential interference with the pharmacodynamic activity and efficacy of KEYTRUDA®. However, systemic corticosteroids or other immunosuppressants can be used after starting KEYTRUDA® to treat immune-mediated adverse reactions (See WARNINGS AND PRECAUTIONS).

NOC/c DOSAGE AND ADMINISTRATION

Patient Selection

Non-Small Cell Lung Carcinoma

Patients should be selected for treatment of metastatic NSCLC with KEYTRUDA[®] based on the presence of positive PD-L1 expression as determined by an experienced laboratory using a validated test. It is preferred that, a test authorized by Health Canada, or one that is equivalent to that used in clinical trials (e.g. PD- L1 IHC 22C3 pharmDxTM kit from Dako; see CLINICAL TRIALS) be considered.

Recommended Dose and Dosage Adjustment (See WARNINGS AND PRECAUTIONS)

Recommended Dosage for Melanoma

The recommended dose of KEYTRUDA® is 2 mg/kg body weight administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity.

Recommended Dosage for NSCLC - Previously Untreated

The recommended dose of KEYTRUDA[®] is 200 mg fixed dose administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression, unacceptable toxicity or up to 24 months in patients without disease progression.

NOC/c - Recommended Dosage for NSCLC - Previously Treated

The recommended dose of KEYTRUDA® is 2 mg/kg body weight administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity.

NOC/c - Recommended Dosage for HL

The recommended dose of KEYTRUDA® is 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks.

Recommended Dosage for Urothelial Carcinoma - Previously Treated

The recommended dose of KEYTRUDA® is 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity, or up to 24 months in patients without disease progression.

Patients should be treated with KEYTRUDA[®] until disease progression or unacceptable toxicity. Atypical responses (i.e., an initial transient increase in tumour size or small new lesions within the first few months followed by tumour shrinkage) have been observed. Clinically stable patients with initial evidence of disease progression may remain on treatment until disease progression is confirmed.

Table 14: Recommended treatment modifications for KEYTRUDA®

Immune-related	Severity	Treatment modification
adverse reactions	·	
Pneumonitis	Moderate (Grade 2)	Withhold until adverse reactions recover to Grade 0-1*
	Severe or life-threatening (Grade 3 or 4), or recurrent moderate (Grade 2)	Permanently discontinue
Colitis	Moderate or severe (Grade 2 or 3)	Withhold until adverse reactions recover to Grade 0-1*
	Life-threatening (Grade 4) or recurrent severe (Grade 3)	Permanently discontinue
Nephritis	Moderate (Grade 2) with creatinine > 1.5 to ≤ 3 times upper limit of normal (ULN)	Withhold until adverse reactions recover to Grade 0-1*
	Severe or life-threatening (Grade 3 or 4) (Grade ≥ 3 with creatinine > 3 times ULN)	Permanently discontinue
Endocrinopathies	Severe or life-threatening (Grade 3 or 4) symptomatic hypophysitis Type 1 diabetes associated with Grade > 3 hyperglycaemia (glucose > 250 mg/dL or > 13.9 mmol/L) or associated with ketoacidosis Hyperthyroidism Grade ≥ 3	Withhold until adverse reactions recover to Grade 0-1* For patients with severe (Grade 3) or life-threatening (Grade 4) endocrinopathy that improved to Grade 2 or lower and is controlled with hormone replacement, if indicated, continuation of KEYTRUDA® may be considered after corticosteroid taper, if needed. Otherwise treatment should be discontinued. Hypothyroidism may be managed with replacement therapy without treatment interruption.
Hepatitis	Moderate (Grade 2) with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 to 5 times upper limit of normal (ULN) or total bilirubin > 1.5 to 3 times ULN	Withhold until adverse reactions recover to Grade 0-1*
	Grade ≥ 3 with AST or ALT > 5 times ULN or total bilirubin > 3 times ULN	Permanently discontinue

	For patients with liver metastasis who begin treatment with moderate (Grade 2) elevation of AST or ALT, if AST or ALT increases $\geq 50\%$ relative to baseline and lasts ≥ 1 week	Permanently discontinue
Skin reactions or Stevens-Johnson	Severe skin reactions (Grade 3) or suspected SJS or TEN	Withhold until adverse reactions recover to Grade 0-1*
syndrome (SJS) or toxic epidermal necrolysis (TEN)	Severe skin reactions (Grade 4) or confirmed SJS or TEN	Permanently discontinue
Other immune- related adverse	Based on severity and type of reaction (Grade 2 or Grade 3)	Withhold until adverse reactions recover to Grade 0-1*
reactions	Severe or life-threatening (Grade 3 or 4) myocarditis or encephalitis	Permanently discontinue
	Life-threatening (Grade 4) or recurrent severe (Grade 3)	Permanently discontinue
Infusion-related reactions	Severe or life-threatening (Grade 3 or 4)	Permanently discontinue

Note: toxicity grades are in accordance with National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4).

In patients with cHL with Grade 4 hematological toxicity, KEYTRUDA[®] should be withheld until adverse reactions recover to Grade 0-1.

Renal Impairment: No dose adjustment is needed for patients with mild (eGFR) < 90 and ≥ 60 mL/min/1.73 m²) or moderate (eGFR < 60 and ≥ 30 mL/min/1.73 m²) renal impairment. KEYTRUDA[®] has not been studied in patients with severe (eGFR < 30 and ≥ 15 mL/min/1.73 m²) renal impairment.

<u>Hepatic Impairment:</u> No dose adjustment is needed for patients with mild hepatic impairment. KEYTRUDA[®] has not been studied in patients with moderate or severe hepatic impairment.

Eastern Cooperative Oncology Group (ECOG) performance status score ≥ 2 : Patients with ECOG performance status score ≥ 2 were excluded from the clinical trials (see CLINICAL TRIALS).

^{*} If corticosteroid dosing cannot be reduced to \leq 10 mg prednisone or equivalent per day within 12 weeks or a treatment-related toxicity does not resolve to Grade 0-1 within 12 weeks after last dose of KEYTRUDA[®], then KEYTRUDA[®] should be permanently discontinued.

Preparation and Administration

Reconstitution of KEYTRUDA® (Lyophilized Powder)

- Prior to reconstitution, the vial of lyophilized powder can be out of refrigeration (temperatures at or below 25°C) for up to 24 hours.
- Aseptically add 2.3 mL of sterile water for injection to yield a 25 mg/mL (pH 5.2-5.8) solution of KEYTRUDA[®].
- To avoid foaming, deliver the water along the walls of the vial and not directly on the lyophilized powder.
- Slowly swirl the vial to allow reconstitution of the lyophilized powder. Allow up to 5 minutes for the bubbles to clear. Do not shake the vial.

Preparation for Intravenous Infusion

- Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. KEYTRUDA[®] is a clear to slightly opalescent, colorless to slightly yellow solution. Discard the vial if visible particles are observed. Dilute KEYTRUDA[®] solution or reconstituted lyophilized powder prior to intravenous administration.
- Withdraw the required volume from the vial(s) of KEYTRUDA® and transfer into an intravenous bag containing 0.9% sodium chloride or 5% glucose (dextrose) to prepare a diluted solution with a final concentration ranging from 1 to 10 mg/mL. Mix diluted solution by gentle inversion.

Storage of Reconstituted and Diluted Solutions

- Do not freeze the infusion solution.
- The product does not contain preservative. The reconstituted and/or diluted product should be used immediately. If not used immediately, reconstituted and diluted solutions of KEYTRUDA® solutions may be stored at room temperature for a cumulative time of up to 6 hours. Reconstituted and diluted solutions of KEYTRUDA® may also be stored under refrigeration at 2°C to 8°C; however, the total time from reconstitution or dilution of KEYTRUDA® to completion of infusion should not exceed 24 hours. If refrigerated, allow the vials and/or IV bags to come to room temperature prior to use.

Administration

- Administer infusion solution intravenously over 30 minutes using a sterile, non-pyrogenic, low-protein binding 0.2 to 5 μm in-line or add-on filter.
- Do not co-administer other drugs through the same infusion line.
- Discard any unused portion left in the vial.

OVERDOSAGE

There is no information on overdosage with KEYTRUDA[®]. The maximum tolerated dose of KEYTRUDA[®] has not been determined. In clinical trials, patients received up to 10 mg/kg with a similar safety profile to that seen in patients receiving 2 mg/kg.

In case of overdose, patients must be closely monitored for signs or symptoms of adverse reactions, and appropriate symptomatic treatment instituted.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

NOC/c ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

PD-1 is an immune-checkpoint receptor that limits the activity of T lymphocytes in peripheral tissues. The PD-1 pathway is an immune control checkpoint that may be engaged by tumour cells to inhibit active T-cell immune surveillance. KEYTRUDA® is a high affinity antibody against PD-1, which exerts dual ligand blockade of the PD-1 pathway, including PD-L1 and PD-L2, on antigen presenting or tumour cells. By inhibiting the PD-1 receptor from binding to its ligands, KEYTRUDA® reactivates tumour-specific cytotoxic T lymphocytes in the tumour microenvironment and thereby also reactivates anti-tumour immunity.

Pharmacodynamics

In peripheral blood of patients who received KEYTRUDA® 2 mg/kg every 3 weeks or 10 mg/kg every 2 weeks or 3 weeks, an increased percentage of activated (i.e., HLA-DR+) CD4+ and CD8+ T-cells was observed after treatment at all doses and schedules without an increase in the circulating T-lymphocyte number.

Pharmacokinetics

The pharmacokinetics of pembrolizumab was studied in 2188 patients with unresectable or metastatic melanoma; with NSCLC; with other solid tumour types who received doses in the range of 1 to 10 mg/kg every 2 or 3 weeks. Population pharmacokinetic analyses were performed in patients with solid tumours (predominantly melanoma) and in patients with NSCLC.

Absorption: KEYTRUDA[®] is dosed via the IV route and therefore is immediately and completely bioavailable.

Distribution: Consistent with a limited extravascular distribution, the volume of distribution of pembrolizumab at steady state is small (approximately 7.5L; Coefficient of Variation (CV): 21%). As expected for an antibody, pembrolizumab does not bind to plasma proteins in a specific manner.

Metabolism: Pembrolizumab is catabolised through non-specific pathways; metabolism does not contribute to its clearance.

Excretion: The systemic clearance of pembrolizumab is - approximately 0.2 L/day (CV: 37%) and the terminal half-life ($t^{1/2}$) is approximately 26 days (CV: 39%).

Exposure to pembrolizumab as expressed by peak concentration (Cmax) or area under the plasma concentration time curve (AUC) increased dose proportionally within the dose range for efficacy. Upon repeated dosing, the clearance of pembrolizumab was found to be independent of

time, and systemic accumulation was approximately 2.2-fold when administered every 3 weeks. Steady-state concentrations of pembrolizumab were reached by 18 weeks; the median C_{min} at steady state was 22.8 mcg/mL during a regimen of 2 mg/kg every 3 weeks.

Table 15: Summary of Pharmacokinetic Parameters

Parameters	Mean*	%CV [†]
Half-life (days)	26	39%
Vdss (L) [‡]	7.5	21%
CL (L/day)	0.2	37%
Time to steady state (weeks)	18	N/A

^{*} Mean values are based on a population pharmacokinetics model

Special Populations and Conditions

The effects of various covariates on the pharmacokinetics of pembrolizumab were assessed in population pharmacokinetic analyses using a two compartment model with linear clearance from the central compartment. The clearance of pembrolizumab increased with increasing body weight; resulting exposure differences are adequately addressed by administration on a mg/kg basis. The following factors had no clinically important effect on the clearance of pembrolizumab: age (range 15-94 years), gender, race, mild or moderate renal impairment, mild hepatic impairment, and tumour burden.

Hepatic Insufficiency: The effect of hepatic impairment on the clearance of pembrolizumab was evaluated by population pharmacokinetic analysis in patients with melanoma and NSCLC with mild hepatic impairment (total bilirubin (TB) 1.0 to 1.5 x ULN or AST > ULN as defined using the National Cancer Institute criteria of hepatic dysfunction) compared to patients with normal hepatic function (TB and AST \leq ULN). No clinically important differences in the clearance of pembrolizumab were found between patients with mild hepatic impairment and normal hepatic function. KEYTRUDA[®] has not been studied in patients with moderate (TB > 1.5 to 3 x ULN and any AST) or severe (TB > 3 x ULN and any AST) hepatic impairment (See WARNINGS AND PRECAUTIONS, and DOSAGE AND ADMINISTRATION).

Renal Insufficiency: The effect of renal impairment on the clearance of pembrolizumab was evaluated by population pharmacokinetic analysis in patients with melanoma and NSCLC with mild (estimated Glomerular Filtration Rate (eGFR) < 90 and \geq 60 mL/min/1.73 m²) or moderate (eGFR < 60 and \geq 30 mL/min/1.73 m²) renal impairment compared to patients with normal (eGFR \geq 90 mL/min/1.73 m²) renal function. No clinically important differences in the clearance of pembrolizumab were found between patients with mild or moderate renal impairment and patients with normal renal function. KEYTRUDA[®] has not been studied in patients with severe (eGFR < 30 and \geq 15 mL/min/1.73 m²) renal impairment (See WARNINGS AND PRECAUTIONS, and DOSAGE AND ADMINISTRATION).

^{† %}CV: coefficient of variation

[‡] Volume of distribution at steady state

STORAGE AND STABILITY

KEYTRUDA® Powder for Solution for Infusion: Store under refrigeration at 2°C to 8°C.

KEYTRUDA[®] Solution for Infusion: Store under refrigeration at 2°C to 8°C. Protect from light. Do not freeze. Do not shake.

For storage conditions after reconstitution or dilution of the medicinal product, see DOSAGE AND ADMINISTRATION.

SPECIAL HANDLING INSTRUCTIONS

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

DOSAGE FORMS, COMPOSITION AND PACKAGING

KEYTRUDA® is supplied as

- Powder for Solution for Infusion: 50 mg lyophilized powder of pembrolizumab in a single-use vial, white to off-white lyophilized powder for reconstitution.
 One vial contains 50 mg of pembrolizumab with a controlled excess fill of 20% (total content per vial 60 mg). After reconstitution with 2.3 mL of sterile water for injection, each 1 mL of solution contains 25 mg of pembrolizumab
- Solution for Infusion: 100 mg/4 mL (25 mg/mL) solution in a single-use vial, clear to slightly opalescent, colorless to slightly yellow solution.

 Each vial of 4 mL contains 100 mg of pembrolizumab with a controlled excess fill of 0.25 mL (total content per vial 4.25 mL).

The following inactive ingredients: L-histidine, polysorbate 80, L-histidine Monohydrochloride Monohydrate, sucrose, and sterile water for injection.

PART II: SCIENTIFIC INFORMATION

KEYTRUDA[®] has been issued marketing authorization **with conditions** for the following patients, pending the results of studies to verify its clinical benefit. Patients should be advised of the nature of the authorization. For further information for KEYTRUDA[®], please refer to Health Canada's Notice of Compliance with conditions – drug products website: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/notices-avis/conditions/index-eng.php

KEYTRUDA[®] is indicated for the treatment of patients with:

- Metastatic non-small cell lung carcinoma (NSCLC) as monotherapy, in adults whose tumours express PD-L1 [(Tumour Proportion Score (TPS) ≥ 1%)] as determined by a validated test and who have disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumour aberrations should have received authorized therapy for these aberrations prior to receiving KEYTRUDA[®].
- refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, in adults who have failed autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) or who are not ASCT candidates and have failed BV.

KEYTRUDA[®] has been issued marketing authorization **without conditions** for the treatment of patients with:

- Unresectable or metastatic melanoma who have not received prior treatment with ipilimumab. Subjects with BRAF V600 mutant melanoma may have received prior BRAF inhibitor therapy.
- Unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor.
- Metastatic non-small cell lung carcinoma (NSCLC) as monotherapy, in adults whose tumours have high PD-L1 expression (TPS ≥50%) as determined by a validated test, with no EGFR or ALK genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC.
- Locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of completing neoadjuvant or adjuvant platinumcontaining chemotherapy.

PHARMACEUTICAL INFORMATION

Drug Substance

Proper Name: pembrolizumab

<u>Structure</u>: pembrolizumab is an IgG4 monoclonal antibody subtype and contains 32 cysteine residues. A correctly folded antibody molecule includes 4 disulfide linkages as interchain bonds and 12 intrachain bonds.

Molecular Weight: The observed molecular weight of the most abundant form of the intact antibody is 149 kDa.

<u>Physical and Chemical Characteristics:</u> is an aqueous solution stored frozen at –40 °C at a concentration of 22.5–27.5 mg/mL in 10 mM histidine buffer, pH 5.2–5.8, containing 7% sucrose and 0.02% polysorbate 80.

The pembrolizumab drug substance solution is colorless to slightly yellow. The solution clarity is clear to opalescent. It is essentially free of extraneous particulates and may contain some proteinaceous particulates.

The pH of pembrolizumab drug substance is 5.2–5.8.

The theoretical extinction coefficient of pembrolizumab at 280 nm is 1.42 L·g⁻¹·cm⁻¹

The pI of pembrolizumab is 6.8–6.9 as determined by capillary isoelectric focusing (cIEF).

CLINICAL TRIALS

Study demographics and trial design Melanoma

KEYNOTE-006: Controlled trial in melanoma patients naïve to treatment with ipilimumab

The safety and efficacy of KEYTRUDA® were investigated in KEYNOTE-006, a multicentre, controlled, Phase III study for the treatment of unresectable or metastatic melanoma in patients who were naïve to ipilimumab and who received no or one prior systemic therapy. Patients were randomized (1:1:1) to receive KEYTRUDA® at a dose of 10 mg/kg every 2 (n=279) or 3 weeks (n=277) or ipilimumab at a dose of 3 mg/kg every 3 weeks (n=278). Randomization was stratified by line of therapy, ECOG performance status, and PD-L1 expression status. The study excluded patients with autoimmune disease or those receiving immunosuppression; previous severe hypersensitivity to other monoclonal antibodies; and HIV, hepatitis B or hepatitis C infection. Patients with BRAF V600E mutant melanoma were not required to have received prior BRAF inhibitor therapy.

Patients were treated with KEYTRUDA[®] until disease progression, unacceptable toxicity, 24 months of therapy, or in the case of complete response, 6 months of therapy plus at least two

doses beyond complete response. Clinically stable patients with initial evidence of disease progression were permitted to remain on treatment until disease progression was confirmed. Assessment of tumour status was performed at 12 weeks, then every 6 weeks through week 48, followed by every 12 weeks thereafter.

Table16: Baseline Characteristics in KEYNOTE-006

Tableto. Dasenne Character	KEYTRUDA ®	KEYTRUDA [®]	Ipilimumab
	10 mg/kg every	10 mg/kg every	-
	3 weeks	2 weeks	
	n=277	n=279	n=278
Men	63%	58%	58%
Women	37%	42%	42%
Age (median)	63	61	62
Age (range)	22-89 years	18-89 years	18-88 years
Prior systemic therapies			
0	67%	66%	65%
1	33%	34%	35%
ECOG PS			
0	68%	70%	68%
1	32%	30%	32%
PD-L1 status*			
Positive	80%	81%	81%
Negative	19%	18%	17%
M-stage at study entry			
M0	3%	3%	5%
M1	1%	2%	2%
M1a	12%	8%	11%
M1b	15%	23%	19%
M1c	68%	64%	64%
Baseline LDH			
normal	63%	69%	64%
elevated	35%	29%	33%
BRAF status			
wild type	64%	63%	61%
V600 mutant	35%	35%	38%
History of Brain Metastases			
No	89%	91%	90%
Yes	10%	8%	10%

^{*} Based on an immunohistochemistry research assay with the 22C3 anti-PD-L1 antibody. PD-L1 positive = membrane expression in \geq 1% of cells within tumour nests as assessed prospectively

The median duration of exposure was 5.6 months (range: 1 day to 11.0 months) for KEYTRUDA[®] and similar in both treatment arms. Fifty-one and 46% of patients received KEYTRUDA[®] 10 mg/kg every 2 or 3 weeks, respectively, for \geq 6 months. No patients in either arm received treatment for more than one year.

Study Results

The primary efficacy outcome measures were overall survival (OS) and progression free survival (PFS; as assessed by Integrated Radiology and Oncology Assessment [IRO] review using Response Evaluation Criteria in Solid Tumours [RECIST 1.1]). Secondary efficacy outcome measures were overall response rate (ORR) and response duration. Table 17 summarizes key efficacy measures, and the Kaplan-Meier curves for OS and PFS are shown in Figures 1 and 2.

Based on a formal interim analysis for OS that occurred at a minimum of 12 months follow up in which 289 deaths were observed, pembrolizumab demonstrated clinically meaningful and statistically significant improvement in OS compared in patients with unresectable or metastatic melanoma previously untreated with ipilimumab. The OS HRs vs. ipilimumab were 0.69 (95% CI: 0.52, 0.90; p 0.00358) for patients treated with KEYTRUDA® 10 mg/kg every 3 weeks and 0.63 (95% CI: 0.47, 0.83; p=0.00052) for patients treated with KEYTRUDA[®] 10 mg/kg every 2 weeks. The OS rate at 12 months was 68.4% (95% CI: 62.5, 73.6) for patients treated with KEYTRUDA[®] 10 mg/kg every 3 weeks, 74.1% (95% CI: 68.5, 78.9) for patients treated with KEYTRUDA® 10 mg/kg every 2 weeks, and 58.2% (95% CI: 51.8, 64.0) for patients treated with ipilimumab. Median OS was not reached for any of the three treatment arms. The PFS HRs vs. ipilimumab were 0.58 (95% CI: 0.47, 0.72; p<0.00001) for patients treated with KEYTRUDA® 10 mg/kg every 3 weeks and 0.58 (95% CI: 0.46, 0.72; p<0.00001) for patients treated with KEYTRUDA® 10 mg/kg every 2 weeks. The median PFS in months was 4.1 (95% CI: 2.9, 6.9) for patients treated with KEYTRUDA[®] 10 mg/kg every 3 weeks, 5.5 (95% CI: 3.4, 6.9) for patients treated with KEYTRUDA[®] 10 mg/kg every 2 weeks, and 2.8 (95% CI: 2.8, 2.9) for patients treated with ipilimumab.

Table 17: Response to KEYTRUDA® 10 mg/kg every 2 or 3 weeks in patients with ipilimumab naïve advanced melanoma in KEYNOTE-006 (Intent-to-Treat Analysis)


Endpoint	KEYTRUDA®	KEYTRUDA [®]	Ipilimumab	
	10 mg/kg every	10 mg/kg every		
	3 weeks	2 weeks		
	n=277	n=279	n=278	
Primary Efficacy Outcome Meas	ure OS			
Number (%) of patients	92 (33%)	85 (30%)	112 (40%)	
with event				
Hazard ratio [†] (95% CI)	0.69 (0.52, 0.90)	0.63 (0.47, 0.83)		
p-Value [‡]	0.00358	0.00052		
Median in months (95% CI)	Not reached	Not reached	Not reached	
	(NA, NA)	(NA, NA)	(13, NA)	
Primary Efficacy Outcome Meas	ure PFS by IRO*			
Number (%) of patients	157 (57%)	157 (56%)	188 (68%)	
with event				
Hazard ratio [†] (95% CI)	0.58 (0.47, 0.72)	0.58 (0.46, 0.72)		
p-Value [‡]	< 0.00001	< 0.00001		
Median in months (95% CI)	4.1 (2.9, 6.9)	5.5 (3.4, 6.9)	2.8 (2.8, 2.9)	
Secondary Efficacy Outcome Measure Best overall response by IRO*				

Endpoint	KEYTRUDA® 10 mg/kg every 3 weeks n=277	KEYTRUDA® 10 mg/kg every 2 weeks n=279	Ipilimumab n=278	
ORR % (95% CI)	33% (27, 39)	34% (28, 40)	12% (8, 16)	
Complete response n (%)	17 (6%)	14 (5%)	4 (1%)	
Partial response n (%)	74 (27%)	80 (29%)	29 (10%)	
Secondary Efficacy Outcome Measure Response duration by IRO*				
Median in months (range)	Not reached	8.3	Not reached	
	(1.4+, 8.1+)	(1.4+, 8.3)	(1.1+, 7.9+)	

IRO = Independent radiology plus oncologist review using RECIST 1.1

NA = not available

Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE-006 Figure 1: (intent to treat population) *



^{*}based on the final analysis with an additional follow-up of 9 months (total of 383 deaths as pre-specified in the protocol)

Hazard ratio (KEYTRUDA® compared to ipilimumab) based on the Cox proportional hazard model stratified by line of therapy, ECOG performance status, and PD-L1 expression status

Based on stratified Log rank test

Based on patients with a best overall response as confirmed complete or partial response




Figure 2: Kaplan-Meier curve for progression-free survival (based on IRO) by treatment arm in KEYNOTE-006 (intent to treat population) *

*based on the final analysis with an additional follow-up of 9 months (total of 566 events)

Sub-population analysis by PD-L1 status

In a subgroup analysis of KEYNOTE-006, the association between PD-L1 expression status using pre-defined 1% expression levels and efficacy measures suggested a clinically important signal predictive of the treatment effect in PFS and OS. In PD-L1 positive patients, pembrolizumab demonstrated improved efficacy vs ipilimumab in ipilimumab-naïve subjects with advanced melanoma across all efficacy endpoints. In contrast, no meaningful difference was detected in efficacy between the treatment groups in the PD-L1 negative patients. Among patients who were evaluable for PD-L1 expression (98%), 82% were PD-L1 positive and 18% were PD-L1 negative. The PFS HRs (pooled pembrolizumab [10 mg/kg every 2 or 3 weeks] vs. ipilimumab) were 0.53 (95% CI: 0.43, 0.65) for PD-L1 positive patients and 0.73 (95% CI: 0.47, 1.11) for PD-L1 negative patients. The OS HRs for pooled pembrolizumab vs. ipilimumab were 0.56 (95% CI: 0.43, 0.73) for PD-L1 positive patients and 0.95 (95% CI: 0.56, 1.62) for PD-L1 negative patients.

Sub-population analysis by BRAF mutation status

A subgroup analysis of KEYNOTE-006 in patients who were BRAF wild type, BRAF mutant without prior BRAF treatment and BRAF mutant with prior BRAF treatment was performed. The PFS hazard ratios (HRs) (pooled KEYTRUDA® [10 mg/kg every 2 or 3 weeks] vs. ipilimumab) were 0.57 (95% CI: 0.45, 0.73) for BRAF wild type, 0.50 (95% CI: 0.32, 0.77) for BRAF mutant without prior BRAF treatment, and 0.73 (95% CI: 0.48, 1.11) for BRAF mutant with prior BRAF treatment. The OS HRs for pooled KEYTRUDA® vs. ipilimumab were 0.61 (95% CI: 0.46, 0.82) for BRAF wild type, 0.69 (95% CI: 0.33, 1.45) for BRAF mutant without prior BRAF treatment, and 0.75 (95% CI: 0.45, 1.26) for BRAF mutant with prior BRAF treatment. ORR for pooled KEYTRUDA® vs. ipilimumab was 34% vs. 13% for BRAF wild type, 41% vs. 13% for BRAF mutant without prior BRAF treatment, and 21% vs. 6% for BRAF mutant with prior BRAF treatment.

KEYNOTE-002: Controlled trial in melanoma patients previously-treated with ipilimumab

Study demographics and trial design

The safety and efficacy of KEYTRUDA® were investigated in KEYNOTE-002, a Phase II multicentre, randomized (1:1:1) controlled study for the treatment of unresectable or metastatic melanoma in patients previously treated with ipilimumab and if BRAF V600 mutation-positive, a BRAF or MEK inhibitor. The treatment arms consisted of KEYTRUDA[®] 2 mg/kg or 10 mg/kg intravenously every 3 weeks or investigator's choice of any of the following chemotherapy regimens: dacarbazine 1000 mg/m2 intravenously every 3 weeks (26%), temozolomide 200 mg/m2 orally once daily for 5 days every 28 days (25%), carboplatin AUC 6 intravenously plus paclitaxel 225 mg/m2 intravenously every 3 weeks for four cycles then carboplatin AUC of 5 plus paclitaxel 175 mg/m2 every 3 weeks (25%), paclitaxel 175 mg/m2 intravenously every 3 weeks (16%), or carboplatin AUC 5 or 6 intravenously every 3 weeks (8%). Randomization was stratified by ECOG performance status (0 vs. 1), LDH levels (normal vs. elevated [≥110% ULN]) and BRAF V600 mutation status (wild-type [WT] or V600E). The trial included patients with unresectable or metastatic melanoma with progression of disease; refractory to two or more doses of ipilimumab (3 mg/kg or higher) and, if BRAF V600 mutation-positive, a BRAF or MEK inhibitor; and disease progression within 24 weeks following the last dose of ipilimumab. The study excluded patients with uveal melanoma and active brain metastasis, autoimmune disease or those receiving immunosuppression; a history of severe or life-threatening immunemediated adverse reactions from treatment with ipilimumab, defined as any Grade 4 toxicity or Grade 3 toxicity requiring corticosteroid treatment (greater than 10 mg/day prednisone or equivalent dose) for greater than 12 weeks; previous severe hypersensitivity to other monoclonal antibodies; a history of pneumonitis or interstitial lung disease; HIV, hepatitis B or hepatitis C infection.

Patients received KEYTRUDA[®] until unacceptable toxicity; disease progression that was symptomatic, was rapidly progressive, required urgent intervention, occurred with a decline in performance status, or was confirmed at 4 to 6 weeks with repeat imaging; withdrawal of consent; or physician's decision to stop therapy for the patient. Assessment of tumor status was performed at 12 weeks after randomization, then every 6 weeks through week 48, followed by every 12 weeks thereafter. Patients on chemotherapy who experienced independently-verified progression of disease after the first scheduled disease assessment were able to crossover and receive 2 mg/kg or 10 mg/kg of KEYTRUDA[®] every 3 weeks in a double-blind fashion.

Table 18: Baseline Characteristics in KEYNOTE-002

Table 10. Baseline Characteristi	KEYTRUDA [®]	KEYTRUDA ®	Chemotherapy*
	2 mg/kg every	10 mg/kg every	
	3 weeks	3 weeks	
	n=180	n=181	n=179
Men	58%	60%	64%
Women	42%	40%	36%
Age (median)	62	60	63
Age (range)	15-87 years	27-89 years	27-87 years
Prior systemic therapies			
At least 2	77%	70%	74%
3 or more	33%	34%	30%
ECOG PS			
0	54%	55%	55%
1	44%	45%	45%
M-stage at study entry			
M0	1%	1%	1%
M1a	5%	7%	8%
M1b	12%	9%	8%
M1c	82%	82%	82%
Baseline LDH			
normal	56%	59%	61%
elevated	43%	40%	39%
BRAF status			
wild type	76%	78%	77%
V600 mutant	24%	22%	24%

^{*} Chemotherapy: dacarbazine, temozolomide, carboplatin plus paclitaxel, paclitaxel, or carboplatin

The median duration of exposure to KEYTRUDA® 2 mg/kg every 3 weeks was 3.7 months (range: 1 day to 32.5 months) and to KEYTRUDA® 10 mg/kg every 3 weeks was 4.8 months (range: 1 day to 31.8 months). The data described below reflect exposure to KEYTRUDA® 2 mg/kg in 37% of patients exposed to KEYTRUDA® for \geq 6 months and in 22% of patients exposed for \geq 12 months. In the KEYTRUDA® 10 mg/kg arm, 41% of patients were exposed to KEYTRUDA® for \geq 6 months and 28% of patients were exposed to KEYTRUDA® for \geq 12 months.

Study Results

The co-primary efficacy outcome measures were PFS (as assessed by IRO review using RECIST 1.1), and OS. Secondary efficacy outcome measures were, ORR and response duration. Table 19 summarizes key efficacy measures in patients previously treated with ipilimumab, and the Kaplan-Meier curves for PFS and OS are shown in Figures 3 and 4. Both pembrolizumab arms were superior to chemotherapy for PFS. There was no statistically significant difference between pembrolizumab and chemotherapy in the final OS analysis that was not adjusted for the

potentially confounding effects of crossover. Of the patients randomized to the chemotherapy arm, 55% crossed over and subsequently received treatment with KEYTRUDA[®].

Table 19: Response to KEYTRUDA® 2 mg/kg or 10 mg/kg every 3 weeks in patients with unresectable or metastatic melanoma in KEYNOTE-002

Endpoint	KEYTRUDA [®] .	KEYTRUDA®.	Chemotherapy
	2 mg/kg every	10 mg/kg every	
	3 weeks	3 weeks	
	n=180	n=181	n=179
PFS [§] by IRO [¶]			
Number (%) of patients with	129 (72%)	126 (70%)	155 (87%)
event			
Hazard ratio [†] (95% CI)	0.57 (0.45, 0.73)	0.50 (0.39, 0.64)	
p-Value [‡]	< 0.0001	< 0.0001	
Median in months (95% CI)	2.9 (2.8, 3.8)	2.9 (2.8, 4.7)	2.7 (2.5, 2.8)
OS*			
Number (%) of patients with	123 (68%)	117 (65%)	128 (72%)
event			
Hazard ratio [†] (95% CI)	0.86 (0.67, 1.10)	0.74 (0.57, 0.96)	
p-Value [‡]	0.117	0.011 ^{-#}	
Median in months (95% CI)	13.4 (11.0, 16.4)	14.7 (11.3, 19.5)	11.0 (8.9, 13.8)

^{*} Based on final analysis

Based on the second interim analysis the ORR was 21% (95% CI: 15, 28), 25% (95% CI: 19, 32) and 4% (95%: CI 2, 9) for the KEYTRUDA® 2mg/kg every 3 weeks, KEYTRUDA® 10mg/kg every 3 weeks, and chemotherapy arms, respectively. ORR consisted of 4 (2%) complete responses and 34 (19%) partial responses for the KEYTRUDA® 2mg/kg treatment arm, 5 (3%) complete responses and 41 (23%) partial responses for the KEYTRUDA® 10mg/kg treatment arm, and 0 (0%) complete responses and 8 (4%) partial responses for the chemotherapy arm.

[†] Hazard ratio (KEYTRUDA® compared to chemotherapy) based on the stratified Cox proportional hazard model


Based on stratified Log rank test

[§] Based on second interim analysis

[¶] IRO = Independent radiology plus oncologist review using RECIST 1.1

^{**} Not statistically significant compared to multiplicity adjusted significance level of 0.01

Figure 3: Kaplan-Meier curve for progression free survival (based on IRO) by treatment arm in KEYNOTE-002 (intent to treat population)






Figure 4: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE-002 (intent to treat population)

Non-Small Cell Lung Carcinoma

KEYNOTE-024: Controlled trial of NSCLC patients naïve to treatment

Study demographics and trial design

The efficacy of KEYTRUDA® was investigated in KEYNOTE-024, a multicenter, open-label randomized, controlled trial. Key eligibility criteria were metastatic NSCLC, PD-L1 expression tumour proportion score (TPS) of 50% or greater by an immunohistochemistry assay using the PD-L1 IHC 22C3 pharmDx® Kit, and no prior systemic treatment for metastatic NSCLC. Patients with EGFR or ALK genomic tumour aberrations; autoimmune disease that required systemic therapy within 2 years of treatment; a medical condition that required immunosuppression; or who had received more than 30 Gy of thoracic radiation within the prior 26 weeks were ineligible. Randomization was stratified by ECOG performance status (0 vs 1), histology (squamous vs non-squamous), and geographic region (East Asia vs. non East-Asia). Patients were randomized (1:1) to receive KEYTRUDA® 200 mg intravenously every 3 weeks (n = 154) or investigator's choice of any of the following platinum-containing chemotherapy regimens (n = 151):

 Pemetrexed 500 mg/m2 every 3 weeks and carboplatin AUC 5 to 6 mg/mL/min every three weeks on Day 1 for 4 to 6 cycles followed by optional pemetrexed 500 mg/m2 every 3 weeks for patients with non-squamous histologies;

- Pemetrexed 500 mg/m2 every 3 weeks and cisplatin 75 mg/m2 every 3 weeks on Day 1 for 4 to 6 cycles followed by optional pemetrexed 500 mg/m2 every 3 weeks for patients with non-squamous histologies;
- Gemcitabine 1250 mg/m2 on days 1 and 8 and cisplatin 75 mg/m2 every 3 weeks on Day 1 for 4 to 6 cycles;
- Gemcitabine 1250 mg/m2 on Days 1 and 8 and carboplatin AUC 5 to 6 mg/mL/min every 3 weeks on day 1 for 4 to 6 cycles;
- Paclitaxel 200 mg/m2 every 3 weeks and carboplatin AUC 5 to 6 mg/mL/min every 3 weeks on Day 1 for 4 to 6 cycles followed by optional pemetrexed maintenance (for non-squamous histologies).

Treatment with KEYTRUDA® continued until RECIST 1.1-defined progression of disease as determined by an independent radiology committee or unacceptable toxicity. Treatment could continue beyond disease progression if the patient was clinically stable and was considered to be deriving clinical benefit by the investigator. Patients without disease progression were treated for up to 24 months or 35 administrations, whichever was longer. Subsequent disease progression could be retreated for up to 1 additional year. Patients on chemotherapy who experienced independently-verified progression of disease were able to crossover and receive KEYTRUDA®.

Table 20: Baseline Characteristics in KEYNOTE-024

	KEYTRUDA ®	Chemotherapy
	200 mg every	
	3 weeks	
	n=154	n=151
Men	60%	63%
Women	40%	37%
Age (median)	65	66
Age (range)	33-90 years	38-85 years
ECOG PS		
0	35%	35%
1	64%	65%
2	1%	0%
Geographic region		
East Asia	14%	13%
Non-East Asia	86%	87%
Histology		
Squamous	19%	18%
Non-squamous	81%	82%
Cancer stage at study entry		
IIIB	1%	1%
IV	99%	99%

The median duration of exposure was 7.0 months (range 1 day to 18.7 months) in the KEYTRUDA® arm and 3.5 months (range 1 day to 16.8 months) in the chemotherapy arm.

Study Results

The primary efficacy outcome measure was PFS as assessed by blinded independent central review (BICR) using RECIST 1.1. Assessment of tumour status was performed every 9 weeks. Secondary efficacy outcome measures were OS and ORR (as assessed by BICR using RECIST 1.1). Table 21 summarizes key efficacy measures for the entire ITT population.

Table 21: Efficacy Results in KEYNOTE-024

Endpoint	KEYTRUDA® 200 mg every	Chemotherapy
	3 weeks	
	n=154	n=151
Primary Efficacy Outcome Measure PFS*		
Number (%) of patients with event	73 (47%)	116 (77%)
Hazard ratio [†] (95% CI)	0.50 (0.37, 0.68)	
p-Value [‡]	< 0.001	
Median in months (95% CI)	10.3 (6.7, NA)	6.0 (4.2, 6.2)
Key Secondary Efficacy Outcome Measure C	OS	
Number (%) of patients with event	44 (29%)	64 (42%)
Hazard ratio [†] (95% CI)	0.60 (0.41, 0.89)	
p-Value [‡]	0.005	
Median in months (95% CI)	Not reached	Not reached
	(NA, NA)	(9.4, NA)
Secondary Efficacy Outcome Measure Object	ctive response rate*	
ORR % (95% CI)	45% (37, 53)	28% (21, 36)
Complete response %	4%	1%
Partial response %	41%	27%

^{*} Assessed by BICR using RECIST 1.1


NA = not available

In exploratory subgroup analyses, a reduced survival benefit of KEYTRUDA $^{\oplus}$ compared to chemotherapy was observed in females as well as in never-smokers. In females, the HR for PFS was 0.75 (95% CI: 0.46, 1.21) and the HR for OS was 0.95 (95% CI: 0.50, 1.83). In never-smokers, the HR for PFS was 0.90 (95% CI: 0.11, 7.59) and the HR for OS was 1.69 (95% CI: 0.19, 15.25).

[†] Hazard ratio (KEYTRUDA® compared to chemotherapy) based on the stratified Cox proportional hazard model

[‡] Based on stratified Log rank test

Figure 5: Kaplan-Meier Curve for Progression-Free Survival by Treatment Arm in KEYNOTE-024 (Intent to Treat Population)






Figure 6: Kaplan-Meier Curve for Overall Survival by Treatment Arm in KEYNOTE-024 (Intent to Treat Population)

NOC/c KEYNOTE-010: Controlled trial in NSCLC patients previously treated with chemotherapy

Study demographics and trial design

The efficacy of KEYTRUDA® was investigated in KEYNOTE-010, a multicenter, randomized, open-label controlled trial. Key eligibility criteria were metastatic NSCLC that had progressed following platinum-containing chemotherapy, and if appropriate, targeted therapy for ALK or EGFR mutations, and PD-L1 expression tumour proportion score (TPS) of 1% or greater by a clinical trial assay version of the PD-L1 IHC 22C3 pharmDx® kit. Patients with autoimmune disease; a medical condition that required immunosuppression; or who had received more than 30 Gy of thoracic radiation within the prior 26 weeks were ineligible. Randomization was stratified by tumour PD-L1 expression (PD-L1 expression TPS ≥50% vs. PD-L1 expression TPS=1-49%), ECOG performance scale (0 vs. 1), and geographic region (East Asia vs. non-East Asia). Patients were randomized (1:1:1) to receive KEYTRUDA® 2 mg/kg intravenously every 3 weeks (n=344), KEYTRUDA® 10 mg/kg intravenously every 3 weeks (n=346) or docetaxel 75 mg/m² intravenously every 3 weeks (n=343). Patients randomized to KEYTRUDA® were permitted to continue until disease progression that was symptomatic, rapidly progressive, required urgent intervention, occurred with a decline in performance status, or confirmation of

progression at 4 to 6 weeks with repeat imaging or for up to 24 months without disease progression.

Table 22: Baseline Characteristics in KEYNOTE-010

	KEYTRUDA®	KEYTRUDA ®	Docetaxel
	2 mg/kg every	10 mg/kg every	75 mg/m ² every
	3 weeks	3 weeks	3 weeks
	n=344	n=346	n=343
Men	62%	62%	61%
Women	38%	38%	39%
Age (median)	63 years	63 years	62 years
Age (range)	29-82 years	20-88 years	33-82 years
ECOG PS			
0	33%	35%	34%
1	67%	65%	65%
2	1%	0%	0%
Geographic region			
East Asia	19%	19%	18%
Non-East Asia	81%	82%	82%
Histology			
Squamous	22%	23%	19%
Non-squamous	70%	71%	70%
Cancer stage at study entry			
IIIB	6%	8%	6%
IV	92%	91%	91%
Brain Metastasis	16%	14%	14%
EGFR Mutant	8%	9%	8%
ALK Translocation Mutant	1%	1%	1%
Prior Lines of Systemic Therapy	,		
One	71%	68%	69%
Two or more	27%	30%	30%

The median duration of exposure to treatment to KEYTRUDA® 2 mg/kg every 3 weeks was 3.5 months (range: 1 day to 22.4 months) and to KEYTRUDA® 10 mg/kg every 3 weeks was 3.5 months (range 1 day to 20.8 months). The median duration of exposure to docetaxel 75 mg/m² every 3 weeks was 2.0 months (range: 1 day to 13.7 months).

Study Results

The primary efficacy outcome measures were OS and PFS as assessed by a Blinded Independent Central Review (BICR) according to RECIST 1.1 in the subgroup of patients with TPS \geq 50% and the overall population with TPS \geq 1%. Assessment of tumour status was performed every 9 weeks. A secondary efficacy outcome measure was ORR in the subgroup of patients with TPS \geq 50% and the overall population with TPS \geq 1%. Table 23 summarizes key efficacy measures for the entire ITT population (TPS \geq 1%) and for the subgroup of patients with TPS \geq 50%. Kaplan-Meier curves for OS (TPS \geq 1% and TPS \geq 50%) are shown in Figures 7 and 8.

Table 23: Response to KEYTRUDA® 2 or 10 mg/kg every 3 Weeks in Previously Treated Patients with NSCLC in KEYNOTE-010, with TPS \geq 1%

Endpoint	KEYTRUDA ®	KEYTRUDA®	Docetaxel
	2 mg/kg every	10 mg/kg every	75 mg/m ² every
	3 weeks	3 weeks	3 weeks
TPS ≥1%			
Number of patients	344	346	343
Primary Efficacy Outcome Me	asure OS		
Number (%) of patients with	172 (50%)	156 (45%)	193 (56%)
event			
Hazard ratio (98.35% CI)*	0.71 (0.55, 0.92)	0.61 (0.47, 0.79)	
p-Value [†]	<0.001 [‡]	<0.001 [‡]	
Median in months (95% CI)	10.4 (9.4, 11.9)	12.7 (10.0, 17.3)	8.5 (7.5, 9.8)
Primary Efficacy Outcome Me	asure PFS ^{‡,§}		
Number (%) of patients with	266 (77%)	255 (74%)	257 (75%)
event			
Hazard ratio (99.80% CI)*	0.88 (0.66, 1.15)	0.79 (0.60, 1.05)	
p-Value [†]	0.068	0.005	
Median in months (95% CI)	3.9 (3.1, 4.1)	4.0 (2.6, 4.3)	4.0 (3.1, 4.2)
Secondary Efficacy Outcome N	Aeasure Overall res	sponse rate [§]	
ORR %¶ (95% CI)	18% (14, 23)	18% (15, 23)	9% (7, 13)

^{*} Hazard ratio (KEYTRUDA® compared to docetaxel) based on the stratified Cox proportional hazard model. The confidence levels correspond to the allocated Type I error of 0.00825 and 0.001 for the OS and PFS endpoints, respectively.

[†] Based on one-sided stratified Log rank test

Statistically significant based on a pre-specified α level of 0.00825 for the two pairwise comparisons versus docetaxel using a Hochberg procedure

[§] Assessed by BICR using RECIST 1.1

[¶] All responses were partial responses.

Figure 7: Kaplan-Meier Curve for Overall Survival by Treatment Arm in KEYNOTE-010 (TPS \geq 1%, Intent to Treat Population)




Figure 8: Kaplan-Meier Curve for Progression-Free Survival by Treatment Arm in KEYNOTE-010 (TPS ≥ 1%, Intent to Treat Population)





Table 24: Response to KEYTRUDA® 2 or 10 mg/kg every 3 Weeks in Previously Treated Patients with NSCLC in KEYNOTE-010, with TPS \geq 50%

Endpoint	KEYTRUDA[®]	KEYTRUDA®	Docetaxel		
	2 mg/kg every	10 mg/kg every	75 mg/m ² every		
	3 weeks	3 weeks	3 weeks		
TPS ≥50%					
Number of patients	139	151	152		
Primary Efficacy Outcome Me	easure OS				
Number (%) of patients with	58 (42%)	60 (40%)	86 (57%)		
event					
Hazard ratio (98.35% CI)*	0.54 (0.35, 0.83)	0.50 (0.33, 0.75)			
p-Value [†]	<0.001 [‡]	<0.001 [‡]			
Median in months (95% CI)	14.9 (10.4, NA)	17.3 (11.8, NA)	8.2 (6.4, 10.7)		
Primary Efficacy Outcome Me	easure PFS ^{‡, §}				
Number (%) of patients with	89 (64%)	97 (64%)	118 (78%)		
event					
Hazard ratio (99.80% CI)*	0.58 (0.37, 0.92)	0.59 (0.38, 0.91)			
p-Value [†]	<0.001 [¶]	<0.001 [¶]			
Median in months (95% CI)	5.2 (4.0, 6.5)	5.2 (4.1, 8.1)	4.1 (3.6, 4.3)		
Secondary Efficacy Outcome Measure Overall response rate [§]					
ORR %# (95% CI)	30% (23, 39)	29% (22, 37)	8% (4, 13)		

^{*} Hazard ratio (KEYTRUDA® compared to docetaxel) based on the stratified Cox proportional hazard model. The confidence levels correspond to the allocated Type I error of 0.00825 and 0.001 for the OS and PFS endpoints, respectively.

- Based on one-sided stratified Log rank test
- [‡] Statistically significant based on a pre-specified α level of 0.00825 for the two pairwise comparisons versus docetaxel using a Hochberg procedure
- § Assessed by BICR using RECIST 1.1
- Statistically significant based on a pre-specified α level of 0.001 for the two pairwise comparisons versus docetaxel using a Hochberg procedure
- [#] All responses were partial responses.

Figure 9: Kaplan-Meier Curve for Overall Survival by Treatment Arm in KEYNOTE-010 (TPS ≥ 50%, Intent to Treat Population)






Figure 10: Kaplan-Meier Curve for Progression-Free Survival by Treatment Arm in KEYNOTE-010 (TPS ≥ 50%, Intent to Treat Population)

In exploratory subgroup analyses, a reduced survival benefit of KEYTRUDA® compared to chemotherapy was observed in patients with tumours harbouring EGFR activating mutations (n=54), never-smokers (n=130) and patients of East Asian Ethnicity (n=126). In patients with tumours expressing PD-L1 with a TPS \geq 1% that received KEYTRUDA® at 2 mg/kg every three weeks, with EGFR activating mutations, the HR for PFS was 1.78 (95% CI: 0.82, 3.85) and the HR for OS was 1.07 (95% CI: 0.49, 2.37). In never smokers, the HR for PFS was 1.33 (95% CI: 0.86, 2.04) and the HR for OS was 0.84 (95% CI: 0.48, 1.49). In patients of East Asian Ethnicity the HR for PFS was 1.38 (95% CI: 0.87, 2.21) and the HR for OS was 1.39 (95% CI: 0.72, 2.68). The efficacy and safety of pembrolizumab in patients with tumours that do not express PD-L1 (TPS < 1%) have not been established.

Efficacy results were similar for the 2 mg/kg and 10 mg/kg KEYTRUDA® arms. Efficacy results for OS were consistent regardless of the age of tumour specimen (new versus archival).

NOC/c Classical Hodgkin Lymphoma

KEYNOTE-013 and KEYNOTE-087: Open-label studies in patients with refractory classical Hodgkin Lymphoma, or those who have relapsed after greater than or equal to 3 prior lines of therapy

Study demographics and trial design

The efficacy of KEYTRUDA® was investigated in 241 patients with refractory classical Hodgkin Lymphoma, or who have relapsed after 3 or more prior lines of therapy including autologous stem cell transplantation (ASCT), enrolled in two multicenter, nonrandomized, open-label

studies (KEYNOTE-013 and KEYNOTE-087). Both studies included patients regardless of PD-L1 expression. Patients with active, non-infectious pneumonitis, an allogeneic hematopoietic stem cell transplant within the past 5 years (or greater than 5 years but with GVHD), active autoimmune disease or a medical condition that required immunosuppression were ineligible for either trial. Patients received KEYTRUDA® 10 mg/kg every 2 weeks (n=31; KEYNOTE-013) or 200 mg every 3 weeks (n=210; KEYNOTE-087) until unacceptable toxicity or documented disease progression. Patients without disease progression could be treated for up to 24 months. Treatment with KEYTRUDA® could be reinitiated for subsequent disease progression and administered for up to 1 additional year. Response was assessed using the revised lymphoma criteria by PET CT scans, with the first planned post-baseline assessment at week 12. The major efficacy outcome measures (ORR, CRR, and duration of response) were assessed by blinded independent central review according to the 2007 revised International Working Group (IWG) criteria. Secondary efficacy outcome measures were PFS and OS.

Among KEYNOTE-013 patients, the baseline characteristics were median age 32 years (6% age 65 or older), 58% male, 94% White; and 45% and 55% had an ECOG performance status 0 and 1, respectively. The median number of prior lines of therapy administered for the treatment of cHL was 5 (range 2 to 15). Eighty-seven percent were refractory to at least one prior therapy, including 39% who were refractory to first line therapy. Seventy-four percent of patients had received auto-SCT, 26% were transplant ineligible; and 42% of patients had prior radiation therapy.

Among KEYNOTE-087 patients, the baseline characteristics were median age 35 years (9% age 65 or older); 54% male; 88% White; and 49% and 51% had an ECOG performance status 0 and 1, respectively. The median number of prior lines of therapy administered for the treatment of cHL was 4 (range 1 to 12). Eighty-one percent were refractory to at least one prior therapy, including 35% who were refractory to first line therapy. Sixty-one percent of patients had received auto-SCT, 38% were transplant ineligible; 17% had no prior brentuximab vedotin use; and 36% of patients had prior radiation therapy.

Study Results

Efficacy results are summarized in Table 25.

Table 25: Efficacy Results in Patients with refractory or relapsed classical Hodgkin Lymphoma

	KEYNOTE-013	KEYNOTE-087
Endpoint	n=31	n=210
Objective Response Rate*		
ORR %, (95% CI)	58% (39.1, 75.5)	68% (61.3, 74.3)
Complete Remission	19%	22%
Partial Remission	39%	46%
Response Duration*		
Median in months (range)	Not reached (0.0+, 21.4+) [†]	Not reached (0.0+, 8.3) ‡

^{*} Assessed by blinded independent central review according to the 2007 revised International Working Group (IWG) criteria

Urothelial Carcinoma

The efficacy of KEYTRUDA[®] was evaluated in KEYNOTE-045, a multicenter, randomized (1:1), active-controlled trial in patients with locally advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy. The trial excluded patients with autoimmune disease or a medical condition that required immunosuppression.

Patients were randomized to receive either KEYTRUDA® 200 mg every 3 weeks (n=270) or investigator's choice of any of the following chemotherapy regimens all given intravenously every 3 weeks (n=272): paclitaxel 175 mg/m² (n=84), docetaxel 75 mg/m² (n=84), or vinflunine 320 mg/m² (n=87). Patients received KEYTRUDA® until unacceptable toxicity or disease progression. Clinically stable patients with initial evidence of disease progression were permitted to remain on treatment until disease progression was confirmed. Patients without disease progression were treated for up to 24 months. Treatment with pembrolizumab could be reinitiated for subsequent disease progression and administered for up to 1 additional year. Assessment of tumor status was performed at 9 weeks after randomization, then every 6 weeks through the first year, followed by every 12 weeks thereafter.

The major efficacy outcomes were OS and PFS as assessed by BICR per RECIST v1.1 at the time of the second interim analysis using the intent-to-treat (ITT) population. These outcomes were also assessed for the subgroup defined by PD-L1 CPS cutoff of \geq 10% (PD-L1 positive). Additional efficacy outcome measures were ORR as assessed by BICR per RECIST v1.1 and duration of response.

Among the 542 randomized patients, the study population characteristics were: median age 66 years (range: 26 to 88), 58% age 65 or older; 74% male; 72% White and 23% Asian; 57% ECOG performance status of 1 or greater; and 96% M1 disease and 4% M0 disease. Eightseven percent of patients had visceral metastases, including 34% with liver metastases. Eighty-six percent had a primary tumor in the lower tract and 14% had a primary tumor in the upper tract. Fifteen percent of patients had disease progression following prior platinum-containing neoadjuvant or adjuvant chemotherapy as the most recent line of therapy. Twenty-one percent had received 2 or more prior systemic regimens in the metastatic setting. Seventy-six percent of

[†] Based on patients (n=18) with a response by independent review.

[‡] Based on patients (n=143) with a response by independent review

patients received prior cisplatin, 23% had prior carboplatin, and 1% were treated with other platinum-based regimens.

The median follow-up time for 270 patients treated with KEYTRUDA® was 10.3 months. The study demonstrated statistically significant improvements in OS and ORR for patients in the ITT population randomized to KEYTRUDA® as compared to chemotherapy. No statistically significant difference was demonstrated between KEYTRUDA® and chemotherapy with respect to PFS. Table 26 and Figure 11 and Figure 12 summarize the key efficacy measures.

Table 26: Efficacy Results in Patients with Urothelial Carcinoma Previously Treated with Chemotherapy

Endpoint	KEYTRUDA® 200 mg every	Chemotherapy	
	3 weeks n=270	n=272	
OS			
Number (%) of patients with event	155 (57%)	179 (66%)	
Hazard ratio* (95% CI)	0.73 (0	.59, 0.91)	
p-Value [†]	0.002		
Median in months (95% CI)	10.3 (8.0, 11.8)	7.4 (6.1, 8.3)	
PFS [‡]			
Number (%) of patients with event	218 (81%)	219 (81%)	
Hazard ratio* (95% CI)	0.98 (0	.81, 1.19)	
p-Value [†]	0	.416	
Median in months (95% CI)	2.1 (2.0, 2.2)	3.3 (2.3, 3.5)	
Objective Response Rate [‡]			
ORR % (95% CI)	21% (16, 27)	11% (8, 16)	
p-Value ^{§,}	0	.001	


^{*} Hazard ratio (KEYTRUDA® compared to chemotherapy) based on the stratified Cox proportional hazard model

[†] Based on stratified Log rank test

[‡] Assessed by BICR using RECIST 1.1

[§] Based on method by Miettinen and Nurminen

Figure 11: Kaplan-Meier Curve for Overall Survival by Treatment Arm in KEYNOTE-045 (Intent to Treat Population)






Figure 12: Kaplan-Meier Estimates of Progression-Free Survival Based on RECIST 1.1 per Central Radiology Assessment All Subjects (ITT Population)

The study also demonstrated a statistically significant improvement in OS favouring KEYTRUDA[®] for patients whose tumours tested positive for PD-L1 CPS \geq 10% [Hazard Ratio (HR) 0.57 (95% CI 0.37, 0.88)].

In exploratory subgroup analyses, a reduced survival benefit of KEYTRUDA[®] monotherapy compared to chemotherapy was observed in patients who were never smokers (n=187), who were classified as Non-White (n=133) (92% of whom identified with Asian ethnicity), or who lived in the East-Asia geographic region (n=106). In never smokers, the HR for OS was 1.06 (95% CI: 0.72, 1.55) and the HR for PFS was 1.13 (95% CI: 0.80, 1.60). In Non-White subjects, the HR for OS was 1.12 (95% CI 0.70, 1.79) and the HR for PFS was 1.48 (95% CI 0.99, 2.23). In subjects from the East-Asia geographic region, the HR for OS was 1.25 (95% CI: 0.72, 2.18) while the HR for PFS was 1.68 (95% CI: 1.05, 2.67).

As with the ITT population, there was no statistically significant difference between KEYTRUDA[®] and chemotherapy with respect to PFS among patients whose tumours tested positive for PD-L1.

TOXICOLOGY

Repeat-dose toxicity

Repeat-dose toxicology studies were carried out in monkeys. In a 1-month study, monkeys received 0, 6, 40 or 200 mg/kg IV pembrolizumab administered weekly for a total of 5 doses followed by a 4 month recovery period. In the 6 month study, monkeys received 0, 6, 40 or 200 mg/kg IV pembrolizumab administered biweekly for a total of 12 doses, followed by a 4-month recovery period. In both studies, all dose levels administered exceeded the recommended human dose and resulted in exposures and peak serum concentrations that were greater than those observed in humans receiving the recommended dose. Pembrolizumab was not associated with any adverse test article-related findings at doses up to 200 mg/kg administered weekly for 1-month (NOAEL (No Observed Adverse Effect Level) > 200 mg/kg) or at doses up to 200 mg/kg administered biweekly for 6 months (NOAEL > 200 mg/kg).

In an exploratory study, 4 chimpanzees with naturally occuring chronic hepatitis B virus (HBV) infection received rising doses of IV pembrolizumab over 5 weeks. Chimpanzees were administered pembrolizumab (IV) doses of 1, 2, 5, 10 and 10 mg/kg on Day 0, 7, 14, 21, and 28, respectively. Two (2) of the four HBV infected chimpanzees had significantly increased levels of serum ALT, AST, and GGT beginning on day 21 and persisting for at least 1 month after the discontinuation of pembrolizumab.

Reproduction

Animal reproduction studies have not been conducted with KEYTRUDA[®]. The central function of the PD-1/PD-L1 pathway is to preserve pregnancy by maintaining immune tolerance to the fetus. Blockade of PD-L1 signaling has been shown in murine models of pregnancy to disrupt tolerance to the fetus and to result in an increase in fetal loss. These results indicate a potential risk that administration of KEYTRUDA[®] during pregnancy could cause fetal harm, including increased rates of abortion or stillbirth.

Development

Fertility studies have not been conducted with pembrolizumab. There were no notable effects in the male and female reproductive organs in a limited number of sexually mature monkeys based on 1-month and 6-month repeat dose toxicity studies.

Special Toxicology Studies

PD-1 deficiency was associated with enhanced inflammatory responses, increased severity of infections and reduced survival in some animal models. Compared to wild-type mice, PD-1 knockout mice infected with *M. tuberculosis* had enhanced inflammatory responses, increased bacterial proliferation and decreased survival. Decreased survival has also been observed in PD-1 knockout mice infected with LCMV.

Carcinogenesis

The carcinogenic potential of pembrolizumab has not been evaluated in long-term animal studies.

Mutagenesis

The genotoxic potential of pembrolizumab has not been evaluated.

Table 27: Summary of Toxicology Studies

	Table 27: Summary of Toxicology Studies Study Type Treatment Species/Test Gender Doses Findings/Conclusion				
Study Type	Duration	-	and No.		Findings/Conclusions
	and	system		(mg/kg) ^a	
	Dosing		per Group		
	Schedule		Group		
Pharmacokinetic	l.		1		
Non-GLP	Single	Monkey/	3F per	0.3, 3 and	The decline of serum
Pharmacokinetic	dose	Cynomolgus	group	30mg/kg	concentration followed
study					multiphasic kinetics.
IV					Slightly greater than
					dose proportional
					exposure between 0.3
					and 3.0 mg/kg and
					approximately linear
					exposure between 3.0
					and 30 mg/kg was
					observed. Anti-drug
					antibodies (ADA)
					were detected in most
					of the treated animals.
					Clearance (CL) and
					terminal half-life
					(t1/2) appeared to be
					dose dependent in the
					dose range tested with CL ranging from 3.7
					to 5.7 mL/day/kg and
					t1/2 ranging from 4 to
					10 days
General Toxicity	<u>I</u>	ı	1	1	1 - 5 mmj 5
Repeat-Dose	1-month	Monkey/	4F, 4M	0, 6, 40, 200	There was no test
Toxicity	Dosing	Cynomolgus	per group		article-related
IV	Period		(dosing		mortality. Test article-
	with 4-		period);		related changes were
	month		2 F, 2M		limited to an increased
	treatment-		per group		incidence of inguinal
	free		(treatment		swelling, and
	Postdose		-free		increased splenic
	Period,		postdose		weights in males
	dosing		period)		receiving 200 mg/kg at
	once				end of the Dosing
	weekly				Period. Both of these

Study Type	Treatment Duration and Dosing Schedule	Species/Test system	Gender and No. per Group	Doses (mg/kg) ^a	Findings/Conclusions
	(total of 5 doses)				findings were not considered adverse and there was no histopathologic correlate. Splenic weights were normal at the necropsy performed after the treatment-free period. Based on the lack of adverse test article-related findings, the NOAEL was > 200 mg/kg
Repeat-Dose Toxicity IV	6-month Dosing Period with 4- month treatment- free Postdose Period, dosing once every other week (total of 12 doses)	Monkey/ Cynomolgus	3F, 3M per group (dosing period); 2F, 2M per group (treatment -free postdose period)	0, 6, 40, <u>200</u>	There were no test article-related antemortem, electrocardiographic or ophthalmic findings. There were no test article-related changes at injection sites. Following the interim and final necropsies, there were no identified test article-related postmortem findings. The NOAEL was > 200 mg/kg
Other Studies				T	T
Tissue Cross- reactivity in vitro	N/A	Cryosections of normal human tissues	n = 3 donors per tissue (~ 32 tissues/do nor)	1, 10 µg/mL MK-3475 pre- complexed with biotinylated secondary antibody	Positive staining of mononuclear leukocyte membranes was considered ontarget binding consistent with the known biology and expression of PD-1. Off-target cross-

Study Type	Treatment Duration and Dosing Schedule	Species/Test system	Gender and No. per Group	Doses (mg/kg) ^a	Findings/Conclusions
Tissue Cross-reactivity in vitro	N/A	Cryosections of normal Cynomolgus monkey tissues	n = 3 donors per tissue (~ 32 tissues/do nor)	1, 10 µg/mL MK-3475 pre- complexed with biotinylated secondary antibody	reactivity staining was noted in the cytoplasm of various cell types/tissues and the stroma (extracellular connective tissue matrix) of many tissues. These off-target findings were interpreted as spurious binding inherent to the experimental conditions of the <i>in vitro</i> tissue cross-reactivity studies with no <i>in vivo</i> toxicological significance. Positive staining of mononuclear leukocyte membranes was considered ontarget binding consistent with the known biology and expression of PD-1. Off-target cross-reactivity staining was noted in the cytoplasm of various cell types/tissues, the extracellular material in the neurohypophysis and the stroma (extracellular connective tissue matrix) of many tissues. These off-target findings were interpreted as spurious

Study Type	Treatment Duration and Dosing Schedule	Species/Test system	Gender and No. per Group	Doses (mg/kg) ^a	Findings/Conclusions
Cytokine Release Studies In vitro	b, c, d, e 4 days culture for cytokine release after Staphyloco ccus enterotoxin B (SEB) stimulation f 48 hr for cytokine release, dry coat assay	b, f Human, normal donors CHuman, advanced metastatic melanoma patients dHuman, prostate cancer patients Cynomolgus monkey	bn = 3 cn = 8 dn = 8 en = 6 fn = 7	b, c, d, e 25, 2.5, 0.25, 0.025, 0.0025, 0.00025 μg/mL b 25 μg/mL f 25, 2.5, 0.25, 0.025, 0.0025, 0.00025 μg/mL for dry coat assay	binding inherent to the experimental conditions of the <i>in vitro</i> tissue cross-reactivity studies with no <i>in vivo</i> toxicological significance. b, c, d MK-3475 enhances SEB-induced IL-2 production from approximately 2- to 4-fold; MK-3475 modestly enhances production TNF-α, IFNγ, IL-6, and IL-17 (less than 2-fold). In the absence of SEB stimulation, MK-3475 did not induce cytokine production. ^e MK-3475 enhances SEB-induced IL-2 production. ^f MK-3475 did not induce cytokine release. Superagonist anti-CD28 induced robust cytokine release.
Other Studies T-cell recall for Tetanus toxoid	^g 7 days	Human donors, recently revaccinated with tetanus toxoid	n = 2	25, 2.5, 0.25, 0.025, 0.0025, 0.00025 µg/mL	MK-3475 enhanced tetanus toxoid-induced production of IFNγ in a dose-dependent manner.

Study Type	Treatment Duration and Dosing Schedule	Species/Test system	Gender and No. per Group	Doses (mg/kg) ^a	Findings/Conclusions
HBV infection	Once per	HBV-	n = 4	All doses	No changes in viral
	week, 5	infected		IV. First	load were observed.
	dose, rising	chimpanzees		dose =	ALT/AST/GGT flares
	dose			1 mg/kg,	were observed in 2
	escalation.			second dose	animals following the
	Post-dose			= 2 mg/kg,	fifth dose (10 mg/kg);
	(last dose)			third dose =	ALT/AST/GGT levels
	period of 1			5 mg/kg,	remained elevated for
	month			fourth and	at least one month.
				fifth dose =	
				10 mg/kg	

For Repeat-Dose Toxicity, the highest NOAEL (No Observed Adverse Effect Level) is underlined.

MK-3475 or control human IgG4 antibody was pre-incubated with heparinized whole blood for 30-60 minutes, and then cultured for 4 days after stimulation with 0.1 μg/mL Staphylococcus enterotoxin B (SEB). Cytokine levels were assessed by immunoassay.

MK-3475 or superagonistic anti-human CD28 antibody were immobilized by air drying directly onto microtiter plates. Human peripheral blood mononuclear cells (PBMC) were cultured in the wells for 48 hr; cytokine levels were assessed by immunoassay.

Peripheral blood mononuclear cells from donors recently revaccinated with tetanus toxoid (TT) were stimulated *in vitro* for 7 days with 1 µg/mL TT in the presence or absence of MK-3475 or a human IgG4 isotype control antibody. Cytokine levels were assessed by immunoassay.

IL-2 = interleukin 2; TNF- α = tumour necrosis factor-alpha; IFN γ = interferon gamma; IL-6 = interleukin 6; IL-17 = interleukin 17

REFERENCES

- 1. Wafula PO, Teles A, Schumacher A, Pohl K, Yagita H, Volk H-D, et al. PD-1 but not CTLA-4 blockage abrogates the protective effect of regulatory T cells in a pregnancy murine model. Am J Reprod Immunol 2009;62:283-92.
- 2. Guleria I, Khosroshahi A, Ansari MJ, Habicht A, Azuma M, Yagita H, et al. A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med 2005;202(2):231-7.
- 3. Hamid O, Robert C, Daud A, et al: Safety and tumour responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44.
- 4. Frebel H, Nindl V, Schuepbach RA, Braunschweiler T, Richter K, Vogel J, et al. Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice. J Exp Med 2012;209(12):2485-99.
- 5. Lázár-Molnár E, Chen B, Sweeney KA, Wang EJ, Liu W, Lin J, et al. Programmed death-1 (PD-1) deficient mice are extraordinarily sensitive to tuberculosis. Proc Natl Acad Sci U S A 2010;107(30):13402-7.
- 6. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al., Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomized dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109-17.
- 7. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al., Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med 2015;372:2018-28.
- 8. Robert C, Schachter J, Long GV, Arance A, Grob JJ, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372(26):2521-32

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

PATIENT MEDICATION INFORMATION

KEYTRUDA® has been issued marketing authorization **with conditions** for the following patients, pending the results of studies to verify its clinical benefit. Patients should be advised of the nature of the authorization. For further information for KEYTRUDA®, please refer to Health Canada's Notice of Compliance with conditions – drug products website: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/notices-avis/conditions/index-eng.php

KEYTRUDA[®] is indicated for the treatment of patients with:

- Metastatic non-small cell lung carcinoma (NSCLC) as monotherapy, in adults whose tumours express PD-L1 [(Tumour Proportion Score (TPS) ≥ 1%)] as determined by a validated test and who have disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumour aberrations should have received authorized therapy for these aberrations prior to receiving KEYTRUDA[®].
- refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, in adults who have failed autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) or who are not ASCT candidates and have failed BV.

KEYTRUDA[®] has been issued marketing authorization **without conditions** for the treatment of patients with:

- Unresectable or metastatic melanoma who have not received prior treatment with ipilimumab. Subjects with BRAF V600 mutant melanoma may have received prior BRAF inhibitor therapy.
- Unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor.
- Metastatic non-small cell lung carcinoma (NSCLC) as monotherapy, in adults whose tumours have high PD-L1 expression (TPS ≥50%) as determined by a validated test, with no EGFR or ALK genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC.
- Locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of completing neoadjuvant or adjuvant platinumcontaining chemotherapy.

What is a Notice of Compliance with Conditions (NOC/c)?

An NOC/c is a form of market approval granted to a product on the basis of **promising** evidence of clinical effectiveness following review of the submission by Health Canada.

Products approved under Health Canada's NOC/c policy are intended for the treatment, prevention or diagnosis of a serious, life-threatening or severely debilitating illness. They have demonstrated promising benefit, are of high quality and possess an acceptable safety profile based on a benefit/risk assessment. In addition, they either respond to a serious unmet medical need in Canada or have demonstrated a significant improvement in the benefit/risk profile over existing therapies. Health Canada has provided access to this product on the condition that sponsors carry out additional clinical trials to verify the anticipated benefit within an agreed upon time frame.

KEYTRUDA® pembrolizumab

Read this carefully before you start taking KEYTRUDA[®] and each time you get an infusion. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about KEYTRUDA[®].

What is $\overrightarrow{KEY}TRUDA^{(0)}$ (key-true-duh) used for?

KEYTRUDA® is a prescription medicine used to treat:

- a kind of skin cancer called melanoma
- a kind of lung cancer called non-small cell lung cancer
- a kind of cancer called urothelial carcinoma, including bladder cancer

KEYTRUDA® may be used when your melanoma:

• has spread or cannot be removed by surgery (advanced melanoma),

KEYTRUDA® may be used when your lung cancer:

- tests positive for "PD-L1" and,
- has spread or cannot be removed by surgery (advanced lung cancer) and,
- If your tumour has an abnormal "EGFR" or "ALK" gene, and you have tried chemotherapy that contains platinum and an EGFR or ALK inhibitor medicine.

KEYTRUDA® may be used to treat classical Hodgkin Lymphoma:

- that has come back after an autologous stem cell transplant (ASCT) and therapy with brentuximab vedotin (BV), or
- that was not suitable for ASCT and has come back after treatment with BV.

It is not known if KEYTRUDA® is safe and effective in children less than 18 years of age.

People get KEYTRUDA® when their cancer has spread or cannot be taken out by surgery.

How does KEYTRUDA® work?

KEYTRUDA® works by helping your immune system fight your cancer.

What are the ingredients in KEYTRUDA®?

The active substance is pembrolizumab.

The other ingredients are L-histidine, polysorbate-80, L-histidine Monohydrochloride Monohydrate, sucrose, and water for infusion.

KEYTRUDA® comes in the following dosage forms:

Powder for solution for infusion, 50 mg per vial Solution for infusion 100 mg/4mL vial

Do not use KEYTRUDA® if:

 you have had a severe allergic reaction to pembrolizumab or any other ingredients in KEYTRUDA[®]

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take $KEYTRUDA^{\otimes}$. Talk about any health conditions or problems you may have, including if you:

- have an autoimmune disease (a condition where the body attacks its own cells), such as Crohn's disease, Ulcerative Colitis or Lupus
- have pneumonia or inflammation of your lungs (called pneumonitis)
- were previously given ipilimumab, another medicine for treating melanoma, and experienced serious side effects because of that medicine
- had an allergic reaction to other monoclonal antibody therapies
- have or have had chronic viral infection of the liver, including hepatitis B (HBV) or hepatitis C (HCV)
- have human immunodeficiency virus (HIV) infection or acquired immune deficiency syndrome (AIDS)
- have liver damage or have had a liver transplant
- have kidney damage or have had a kidney transplant
- have had a solid organ transplant or a bone marrow (stem cell) transplant that used donor stem cells (allogeneic)
- take other medicines that make your immune system weak. Examples of these may include steroids, such as prednisone.

There are possible side effects of KEYTRUDA® treatment in people who have received a transplant.

- **Rejection of a transplanted organ.** People who have had an organ transplant may have an increased risk of organ transplant rejection. Your doctor should tell you what signs and symptoms you should report and monitor you, depending on the type of organ transplant that you have had.
- Complications, including graft-versus-host-disease (GVHD) in people with bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be severe and can lead to death. They may occur if you had this kind of transplant in the past or if you get it in the future. Your doctor will monitor you for the following signs and symptoms: skin rash, liver inflammation, abdominal pain and diarrhea.

Pregnancy

- If you are pregnant, think you may be pregnant or are planning to have a baby, tell your doctor.
- KEYTRUDA[®] can cause harm or death to your unborn baby.
- You must use effective contraception while you are being treated with KEYTRUDA® and for at least 4 months after the last dose of KEYTRUDA® if you are a woman who could become pregnant.

Breast-feeding

- If you are breast-feeding, tell your doctor.
- Do not breast-feed while taking KEYTRUDA[®].

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

How you are given KEYTRUDA®:

- Your doctor will give you KEYTRUDA® through an infusion into your vein (IV) for about 30 minutes.
- Most people get KEYTRUDA® every 3 weeks.
- Your doctor will decide how many treatments you need.

Usual dose:

Melanoma and previously treated Metastatic Non Small Cell Lung Cancer:

The recommended dose is 2 mg of pembrolizumab per kilogram of your body weight.

Previously untreated Non Small Cell Lung Cancer and Urothelial Carcinoma:

The recommended dose is 200 mg.

Classical Hodgkin Lymphoma:

The recommended dose is 200 mg.

Overdose:

If you think you have taken too much KEYTRUDA®, contact your healthcare professional, hospital emergency department or regional poison control centre immediately, even if there are no symptoms.

If you miss an appointment to get KEYTRUDA®

- Call your doctor right away to reschedule your appointment.
- It is very important that you do not miss a dose of this medicine.

What are possible side effects from using KEYTRUDA®?

When you get KEYTRUDA[®], you can have some serious side effects. You may experience more than one side effect at the same time. The following lists do not include all the possible side effects you may feel when taking KEYTRUDA[®]. If you experience any side effects not listed here, contact your healthcare professional.

The following side effects have been reported in clinical trials:

Very common (may affect more than 1 in 10 people)

- diarrhea, nausea
- itching, rash
- joint pain
- feeling unusually tired or weak
- fever
- feeling less hungry
- shortness of breath
- patches of skin which have lost colour (vitiligo)

Common (may affect more than 2 in 100 people and up to 1 in 10 people)

- flu-like illness
- dry mouth
- headache
- change in your sense of taste
- cough
- lack of white blood cells
- rapid heart beat
- cold sores
- upper respiratory tract infection
- stuffy nose
- stomach pain, constipation, vomiting, inflammation of the mucous membrane in the mouth dry skin, redness of the skin, red raised skin rash
- back pain, muscle aches
- chills
- swelling of the face, legs or arms

- changes in test results:
 - o decrease in the number of red blood cells
 - o decrease in the number of white blood cells
 - o abnormal liver enzyme levels in the blood
 - o decreased sodium levels in the blood
 - o abnormal levels of thyroid stimulating hormone in the blood
 - o weight loss
 - o weight gain

If you have any of the following conditions, call or see your doctor right away. Your doctor may give you other medicines in order to prevent more severe complications and reduce your symptoms. Your doctor may withhold the next dose of KEYTRUDA $^{\text{®}}$ or stop your treatment with KEYTRUDA $^{\text{®}}$.

Serious side effects and what to do about them					
Commentains / official	Talk to your health	care professional			
Symptom / effect	Only if severe	In all cases			
COMMON					
Inflammation of the lungs (pneumonitis) which can		\checkmark			
cause shortness of breath, chest pain, or coughing					
Inflammation of the intestines (colitis) which can cause					
diarrhea or more bowel movements than usual, black,		ما			
tarry, sticky stools or stools with blood or mucus, severe		٧			
stomach pain or tenderness, nausea, vomiting					
Inflammation of the pituitary or thyroid gland					
(hypophysitis, hypopituitarism, including secondary					
adrenal insufficiency; hyperthyroidism,					
hypothyroidism) which can cause rapid heart beat,					
weight loss, increased sweating, weight gain, hair loss,		\checkmark			
feeling cold, constipation, voice getting deeper, muscle					
aches, dizziness or fainting, headaches that will not go					
away or unusual headache, feeling more hungry or					
thirsty, urinating more often than usual.					
Skin problems which can cause rash, itching; skin					
blistering, peeling, or sores; ulcers in mouth or in lining		\checkmark			
of nose, throat, or genital area					
UNCOMMON		√			
Inflammation of the liver (hepatitis) which can cause					
nausea or vomiting, feeling less hungry, pain on the					
right side of stomach, yellowing of skin or whites of					
eyes, dark urine, bleeding or bruising more easily than					
normal					
Inflammation of the kidneys (nephritis) which can cause		\checkmark			
changes in the amount or colour of your urine					
Muscle problems, which can cause muscle pain or		J			
weakness, severe or persistent muscle or joint pains;		*			

Serious side effects and what to do about them					
Symptom / affact	Talk to your healthcare professional				
Symptom / effect	Only if severe	In all cases			
low red blood cell count (anemia).					
Eye problems, which can cause changes in eyesight		√			
Shortness of breath, irregular heartbeat, feeling		ما			
tired, or chest pain (myocarditis).		٧			
Blood sugar problems (type 1 diabetes mellitus) which					
can cause hunger or thirst, a need to urinate more often,		√			
or weight loss					
Confusion, fever, memory problems, or seizures		\ \ \			
(encephalitis)		٧			
Swollen lymph nodes, rash or tender lumps on skin,		\ \ \			
cough, or eye pain (sarcoidosis)		٧			
Inflammation of the pancreas(pancreatitis), which can		ا ا			
cause abdominal pain, nausea, and vomiting		٧			
Reactions related to the infusion such as shortness of		,			
breath, itching or rash, dizziness, or fever, wheezing,		√			
flushing, feeling like passing out.					

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

Reporting Side Effects

You can help improve the safe use of health products for Canadians by reporting serious and unexpected side effects to Health Canada. Your report may help to identify new side effects and change the product safety information.

3 ways to report:

- Online at MedEffect (https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html);
- By calling 1-866-234-2345 (toll-free);
- By completing a Consumer Side Effect Reporting Form and sending it by:
 - Fax to 1-866-678-6789 (toll-free), or
 - Mail to: Canada Vigilance Program

Marketed Health Products Safety and Effectiveness Information Bureau

Marketed Health Products Directorate

Health Products and Food Branch

Health Canada,

Address Locator 1908C

Ottawa, ON

K1A 0K9

Postage paid labels and the Consumer Side Effect Reporting Form are available at MedEffect (https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html).

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Also, to report an adverse event related to KEYTRUDA®, please contact Merck Canada at 1-800-567-2594.

Storage:

It is unlikely that you will be asked to store KEYTRUDA® yourself. It will be stored in the hospital or clinic where it is given to you.

Keep this medicine out of the sight and reach of children.

Powder for Solution for Infusion: Store in a refrigerator (2°C to 8°C). Solution for Infusion: Store in a refrigerator (2°C to 8°C). Protect from light.

If you want more information about KEYTRUDA®:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website (https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html); or Merck Canada website http://www.merck.ca, or by calling Merck Canada at 1-800-567-2594.

To report an adverse event related to KEYTRUDA®, please contact 1-800-567-2594.

This leaflet was prepared by Merck Canada Inc.

Last Revised: March 23, 2018

© 2015, 2017 Merck Canada Inc. All rights reserved.

[®] Merck Sharp & Dohme Corp. Used under license.